


14-16 NOVEMBER 2016 | ADELAIDE, AUSTRALIA



2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE

16-18 NOVEMBER 2016 | ADELAIDE, AUSTRALIA

2016 AUSTRALASIAN HIV/AIDS CONFERENCE



CONFERENCE HANDBOOK

PROUDLY SPONSORED BY GILEAD



SPONSORS

2016 AUSTRALASIAN
SEXUAL HEALTH CONFERENCE



PLATINUM SPONSOR



SILVER SPONSOR



BRONZE SPONSOR



BRONZE SPONSOR



CONFERENCE SUPPORTER



CONFERENCE SUPPORTER

SPONSORS

2016 AUSTRALASIAN
HIV & AIDS CONFERENCE



PLATINUM SPONSOR



Bristol-Myers Squibb

PLATINUM SPONSOR



SILVER SPONSOR



CONFERENCE SUPPORTER



CONFERENCE SUPPORTER

For further information on sponsorship opportunities
for 2017 please contact the Conference Secretariat at:

T +61 2 8204 0770

F +61 2 8204 0782

E info@hivaidsconference.com.au

E info@shconference.com.au

Locked Mail Bag 5057
Darlinghurst NSW 1300 Australia

CONTENTS

| | |
|----------------------|----|
| WELCOME LETTERS | 2 |
| INVITED SPEAKERS | 9 |
| GENERAL INFORMATION | 15 |
| ASSOCIATED EVENTS | 18 |
| FLOOR PLANS AND MAPS | 24 |
| EXHIBITION DIRECTORY | 27 |
| PROGRAM | 32 |
| POSTER LISTING | 53 |

Published in 2016

by the Australasian Society for HIV,
Viral Hepatitis and Sexual Health
Medicine

National Office:

Locked Mail Bag 5057, Darlinghurst
NSW 1300, Australia

T +61 2 8204 0700

F +61 2 8204 0782

E ashm@ashm.org.au

W www.ashm.org.au

ABN: 48 264 545 457

© ASHM 2016

Design and layout by ASHM.

Printed by TTR Print.

Conference ENVIRONMENT POLICY

ASHM Conference, Sponsorship and Events Division implements a waste-reduction policy that addresses: Reduce, Reuse, Recycle. This is done before, during and after each Conference. Our waste-reduction policy aims to implement the following strategies:

- Reduce the number of printed materials by using electronic communication means wherever possible, including the website, email, online registration and abstract submission.
- Monitor final delegate numbers for an accurate forecast of catering requirements in order to avoid waste.
- Research and prioritise purchasing items and equipment that support the use of recycled materials or can be recycled after use.
- Ensure that recycling bins are available onsite at all events.
- Minimize travel through the use of teleconferences instead of face-to-face meetings and holding meetings only when necessary.
- Encourage all Conference stakeholders to consider the environment by suggesting the following: reduction in printing requirements; recycling Conference materials; and reusing Conference merchandise.

Rethinking SEXUAL HEALTH

Dear Delegates

A warm welcome to the 2016 Australasian Sexual Health Conference, here in Adelaide, the capital of the State of Land, Sea and Vines!

We have an exciting and interesting scientific programme of cutting edge research, innovative ideas and lively debate on the theme of “Rethinking Sexual Health”.

It will invite delegates to think “outside the square” and will provide a stimulating environment to share ideas on any aspect of sexual health.

Delegates will hear from speakers involved in the promotion of optimal sexual health including clinicians, researchers, educators and policy makers. This chance to come together, to share experiences and new research has been made possible by the Australasian Sexual Health Alliance (ASHA), a group of partner organisations established to improve national and local responses to sexual health issues through a multidisciplinary support network for the sexual health workforce.

We aim to strengthen the bonds between Sexual Health and Infectious Diseases Physicians, General Practitioners, Nurses, Researchers, Educators, Allied Health Professionals, interested community members and other key contributors to the sexual health sector. We trust you will make the most of the opportunity to network across the very many disciplines that contribute to sexual health, and that you will be open to new ideas that can make a difference to sexual health outcomes.

Enjoy the conference and make the most of what the City of Churches and the Centre for Arts, Fine Wine and Dining has to offer!

Professor Meredith Temple-Smith, Convenor

Dr Carole Khaw, Co-Convenor

WELCOME

TO THE 2016
AUSTRALASIAN
SEXUAL HEALTH
CONFERENCE

Dear friends and colleagues,

The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) and our National Program Committee greatly appreciates your support of this annual conference.

We feel that your attendance in person will be of great benefit. What you can't get from viewing the sessions from your PC at home/work is the overall experience – the gestalt of the whole event: the vibe of a delegation meeting together; the occasions to talk with colleagues; and the ability to have and link several conversations together from attending various program events. The sharing of ideas is very exciting.

Just about everything has changed in HIV in recent years, and this conference presents the best opportunity to understand how these significant shifts are affecting the response to HIV in Australia and our region. This conference provides a unique opportunity to understand the epidemic in its context – social, political as well as biomedical.

The Australasian HIV&AIDS Conference is one of the few meetings at which the entire HIV sector - affected communities, clinicians, researchers, educators and policymakers - get together to identify new ways forward and debate progress in tackling HIV. The exposure to this range of perspectives is vital to remain informed and engaged.

We're very pleased that the Sexual Health Conference is once again running back-to-back. We're coming to a point where people truly understand that you can't talk about HIV without talking about STIs [and vice versa] – HIV being one of those important STIs.

Once again thank you for your valuable time in attending the conference and we look forward to a wonderful conference here in Adelaide.

National Program Organising Committee

WELCOME

TO THE 2016
AUSTRALASIAN
HIV & AIDS
CONFERENCE



COMMITTEE

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE


SEXUAL HEALTH CORE ORGANISING COMMITTEE

| | |
|-----------------------|---|
| Meredith Temple-Smith | Convenor University of Melbourne |
| Carole Khaw | Co-Convenor Royal Adelaide Hospital |
| Peter Aggleton | Centre for Social Research in Health, UNSW |
| Deborah Bateson | Family Planning NSW |
| Emma Clements | Royal Adelaide Hospital |
| Jill Davidson | Shine SA |
| Heather Jolly | NSW Health |
| Megan Lim | Burnet Institute Centre for Population Health |
| Lea Narciso | Department of Health South Australia |
| Alison Ward | Royal Adelaide Hospital |
| Lynne Wray | Family Planning NSW |

SEXUAL HEALTH SCIENTIFIC COMMITTEE

| | |
|------------------|--|
| David Templeton | Chair Kirby Institute NSW |
| Carole Khaw | Co-Convenor Royal Adelaide Hospital |
| Peter Aggleton | Centre for Social Research in Health, UNSW |
| Deborah Bateson | Family Planning NSW |
| Charlotte Bell | Royal Adelaide Hospital |
| Michael Burke | The Royal Australian College of General Practitioners |
| Ellie Freedman | Forensic and Medical Sexual Assault Clinicians Australia |
| Jane Hocking | University of Melbourne |
| Louise Johnson | Victorian Assisted Reproductive Treatment Authority |
| Jayne Lucke | Australian Research Centre in Sex, Health and Society |
| Kathleen McNamee | Family Planning Victoria |
| Graham Neilsen | Stonewall Medical Centre |
| Lara Roeske | The Royal Australian College of General Practitioners |
| James Ward | South Australian Health and Medical Research Institute |
| Lyndall Young | Forensic and Medical Sexual Assault Clinicians Australia |

JOINT CONFERENCE SECRETARIAT

| | |
|--|-------------------------------------|
|  ashm conference and events division | Amanda Burg, Senior Project Officer |
| | Amy Sargent, Project Officer |

COMMITTEE

2016 AUSTRALASIAN HIV & AIDS CONFERENCE

NATIONAL PROGRAM COMMITTEE CORE GROUP

| | |
|------------------|--|
| Levinia Crooks | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine |
| Daniel Gallant | Department of Health South Australia |
| Bridget Haire | Kirby Institute, UNSW |
| Martin Holt | Centre for Social Research in Health, UNSW |
| Jennifer Hoy | The Alfred Hospital and Monash University |
| Kath Leane | HIV South Australia / NAPWHA |
| Scott McGill | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine |
| Darryl O'Donnell | The Australian Federation of AIDS Organisations |
| Damian Purcell | University of Melbourne |
| Simon Ruth | Victorian AIDS Council |
| David Templeton | Kirby Institute, UNSW |
| James Ward | South Australian Health and Medical Research Institute |
| Steve Wesselingh | South Australian Health and Medical Research Institute |

THEME A

| | |
|---------------------------|--|
| Damian Purcell (Convenor) | University of Melbourne |
| Chantelle Ahlenstiel | Kirby Institute, UNSW |
| Jenny Anderson | Doherty Institute |
| Kieran Cashin | Burnet Institute |
| Melissa Churchill | Burnet Institute |
| Sarah Palmer | Centre for Virus Research at Westmead Millennium Institute |
| Stuart Turville | Kirby Institute, UNSW |
| Steve Wesselingh | South Australian Health and Medical Research Institute |
| Adam Wheatley | Doherty Institute |

THEME B

| | |
|-------------------------|--|
| Jennifer Hoy (Convenor) | The Alfred Hospital and Monash University |
| Brent Allan | Living Positive Victoria |
| Phillip Cunningham | NSW State Reference Laboratory |
| Julian Elliott | Monash University |
| Sam Libertino | Fiona Stanley Hospital |
| James McMahon | The Alfred Hospital |
| Limin Mao | Centre for Social Research in Health, UNSW |
| Kathy Petumenos | Kirby Institute, UNSW |
| Brett Ritchie | Royal Adelaide Hospital |
| Steve Ritchie | Auckland District Health Board |
| Steven Wade | Kensington Road Medical Centre |

THEME C

| | |
|------------------------|--|
| Martin Holt (Convenor) | Centre for Social Research in Health, UNSW |
| Daniel Gallant | Department of Health South Australia |
| James Gray | ACON |
| Rebecca Guy | Kirby Institute, UNSW |
| Wills Logue | South Australia Mobilisation + Empowerment for Sexual Health |
| Jennifer Power | Australian Research Centre in Sex, Health & Society (ARCSHS) |
| Katy Roy | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine |
| Mark Stooze | Burnet Institute |
| Iryna Zablotska | Kirby Institute, UNSW |

THEME D

| | |
|--------------------------|--|
| Bridget Haire (Convenor) | Kirby Institute, UNSW |
| Lisa Bastian | Department of Health, WA |
| Stephen Bell | Kirby Institute, UNSW |
| Suzanne Blogg | NPS Medicine Wise |
| Aaron Cogle | NAPWHA |
| Scott McGill | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine |
| Christy Newman | Centre for Social Research in Health |
| Duc Nguyen | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine |
| Enaam Oudih | CALD/ Relationships Australia (SA) |
| Patrick Rawstorne | School of Public Health & Community Medicine, UNSW |
| Ben Wilcox | The Australian Federation of AIDS Organisations |

ABORIGINAL AND TORRES STRAIT ISLANDER COMMITTEE

| | |
|-----------------------|--|
| James Ward (Convenor) | South Australian Health and Medical Research Institute |
| Darren Braun | Queensland Aboriginal and Islander Health Council |
| Michael Larkin | Aboriginal Health Council of SA |
| Roberta Mongoo | Wirraka Maya Health Service Aboriginal Corporation, WA |
| Jennifer Needham | Aboriginal Health Council of Western Australia |
| Damien Ralphs | SHine SA |
| Melinda Hassall | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine |

JOINT CONFERENCE SECRETARIAT

| | |
|---|-------------------------------------|
|  ashm conference and events division | Amanda Burg, Senior Project Officer |
| | Amy Sargent, Project Officer |

Choose DOLUTEGRAVIR AS YOUR CORE AGENT



Flexibility to build a
tailored treatment regimen¹



Please review Product Information before prescribing. Product Information is available from ViiV Healthcare Australia at www.viivhealthcare.com.au or on 1800 499 226.

PBS Information: This product is listed on the PBS as a section 100 item. Refer to PBS Schedule for full authority information.

Minimum Product Information: TIVICAY® (dolutegravir) tablets

Indications: Treatment of HIV infection in combination with other antiretroviral agents in adults and children > 12 years of age and weighing ≥ 40 kg. **Contraindications:** In combination with dofetilide. Known hypersensitivity to TIVICAY or any of the excipients. **Precautions:** Discontinue TIVICAY immediately if hypersensitivity reaction occurs. Refer to Product Information for more information on hypersensitivity. As with other antiretrovirals, immune reconstitution syndrome may arise in patients with severe immune deficiency. Monitor liver chemistries in patients with hepatitis B and/or C co-infection. Apply diligence in maintaining effective hepatitis B therapy when starting TIVICAY-based therapy in co-infected patients. Caution in integrase inhibitor (INI)-experienced patients with severe renal impairment as decrease in dolutegravir concentrations may lead to resistance. Pregnancy (category B1). Breastfeeding not advised. Use in children < 12 years or < 40 kg, adolescents < 18 years with resistance to INI and elderly ≥ 65 years has not been established. **Interactions:** Recommended dose 50mg BD when coadministered with efavirenz (without boosted protease inhibitors), efavirenz, nevirapine, tipranavir/ritonavir, rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John's wort. Administer TIVICAY 2 hours before or 6 hours after polyvalent cation-containing antacids, or calcium or iron supplements, alternatively administer calcium/iron supplements with food. Dose adjustment of concomitant metformin should be considered. **Adverse Effects:** Treatment-emergent adverse reactions of grades 2-4 and ≥ 2% frequency in treatment-naïve pivotal trials: insomnia, headache, fatigue (TIVICAY 50mg QD). Treatment-emergent ADRs in INI-resistant patients (TIVICAY 50 mg BD) generally similar to 50mg QD in adult Phase 3 trials. **Dosage & Administration:** Adults without resistance to INI or adolescents (12 to < 18 years and ≥ 40 kg) not previously treated with INI: 50 mg once daily. Adults with resistance to INI, or when coadministered with efavirenz (without boosted protease inhibitor), efavirenz, nevirapine, tipranavir/ritonavir, rifampicin, carbamazepine, phenytoin, phenobarbital or St. John's wort: 50 mg twice daily. Can be taken with or without food.

Reference: 1. Tivicay approved product information



For information on ViiV products or to report an adverse event involving a ViiV product, please contact GSK Medical Information on 1800 499 226. ViiV Healthcare Pty Ltd, Level 3, 436 Johnston St, Abbotsford VIC 3067, ACN 138 687 448. TRIUMEQ® and TIVICAY® are registered trade marks of the ViiV Healthcare Group of Companies. Date of preparation: October 2016. AUS/DTGP/0016/16a.Etal6606VII

Choose DOLUTEGRAVIR AS YOUR CORE AGENT



Simplicity of dolutegravir
in a single-pill regimen for
HLA-B*5701 negative patients¹



Please review Product Information before prescribing. Product Information is available from ViiV Healthcare Australia at www.viivhealthcare.com.au or on 1800 499 226.

PBS Information: This product is listed on the PBS as a section 100 item. Refer to PBS Schedule for full authority information.

Minimum Product Information: Triumeq® (dolutegravir 50 mg, abacavir 600 mg and lamivudine 300 mg) tablets

Warning: Abacavir, a component of TRIUMEQ® tablets, is associated with hypersensitivity reactions, which can be life-threatening, and in rare cases fatal. TRIUMEQ® tablets, or any other medicinal product containing abacavir (KIVEXA® [abacavir/lamivudine], TRIZIVIR® [abacavir/lamivudine/zidovudine] and ZIAGEN® [abacavir]), MUST NEVER be restarted following a hypersensitivity reaction. (see Precautions and Adverse Effects).

Indications: Treatment of HIV infection in adults and adolescents ≥ 12 years old who are antiretroviral treatment-naïve or are infected with HIV without documented or clinically suspected resistance to dolutegravir, abacavir or lamivudine. **Contraindications:** Known hypersensitivity to dolutegravir, abacavir or lamivudine, or to any of the excipients; in combination with dofetilide or pilsicainide. **Clinically Significant Precautions:** Screen for HLA-B*5701 prior to initiation or re-initiation of abacavir; abacavir hypersensitivity reaction can occur at any time during treatment and is still possible even in the absence of HLA-B*5701. Hypersensitivity to dolutegravir, lactic acidosis/ severe hepatomegaly with steatosis, lipodystrophy, immune reconstitution syndrome and autoimmune disorders may occur. Discontinuation of lamivudine in patients co-infected with HBV may cause recurrent hepatitis. Consider underlying risk of coronary heart disease and minimise modifiable risks. Not recommended in the following: breastfeeding, adults or adolescents < 40 kg, children < 12 years old, and patients with creatinine clearance < 50 mL/min, hepatic impairment or resistance to integrase inhibitors. Limited data in elderly ≥ 65 years old. Pregnancy (B3). **Clinically Significant Interactions:** See Product Information for full list of interactions. **Adverse Effects:** Adverse reactions and laboratory abnormalities of grades 2-4 and $\geq 2\%$ on dolutegravir + abacavir/lamivudine in treatment-naïve clinical trial: insomnia, headache, fatigue, alanine transferase, aspartate transferase, creatine kinase, hyperglycaemia, lipase, total neutrophils. Common post-marketing reactions reported for abacavir or lamivudine: hyperlactataemia, rash, alopecia, arthralgia, muscle disorders. **Dosage & Administration:** One tablet once daily, taken with or without food.

Reference: 1. Triumeq approved product information



For information on ViiV products or to report an adverse event involving a ViiV product, please contact GSK Medical Information on 1800 499 226. ViiV Healthcare Pty Ltd, Level 3, 436 Johnston St, Abbotsford VIC 3067, ACN 138 687 448. TRIUMEQ®, TIVICAY®, KIVEXA®, 3TC®, TRIZIVIR®, ZIAGEN® are registered trade marks of the ViiV Healthcare Group of Companies. Date of preparation: October 2016. AUS/DTGP/0016/16.Etal6606VII

INVITED SPEAKERS

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE



DR AMBER D'SOUZA

Amber D'Souza is an Associate Professor Epidemiology at the Johns Hopkins Bloomberg School of Public Health.

Dr. D'Souza leads a research program on infectious causes of cancer, focusing on understudied areas such as anal cancer among MSM, and oral HPV causing tonsillar cancers.

She is the co-PI of the datacentre for the Multicentre AIDS Cohort Study (MACS).



A/PROF MARION SAVILLE

Marion is a NZ medical graduate who trained in pathology in the US, specialising in cytopathology.

Her major interest lies in the prevention of cervical cancer through HPV vaccination and cervical screening.

She is Executive Director of the Victorian Cytology Service.



BASIL DONOVAN

Professor Donovan is Head of the Sexual Health Program at the Kirby Institute, UNSW Australia, and he practises at the Sydney Sexual Health Centre, Sydney Hospital.



PROF MARK HAYTER

Mark Hayter is Professor and Head of the Nursing Department at the University of Hull, United Kingdom.

He qualified as a nurse in 1987 and holds a Bachelors Degree in the Social Dimensions of Health and a Masters Degree in Clinical Nursing. His PhD, a sociological analysis of family planning consultations, was awarded in 2004 from the University of Sheffield, UK.

Mark is a Visiting Professor at the University of Genoa, Italy and has extensive academic contacts in Asia, Australia, the Middle East and the United States. He was Visiting Professor at the Hong Kong Polytechnic University 2012-2015.

Mark is an Editor of the Journal of Advanced Nursing and has previously edited the Journal of Clinical Nursing. He serves on the editorial boards of the Journal of School Nursing, Sex Education, the International Journal of Qualitative Methodology, Nursing Outlook and the Journal of Nursing Interventions.

He is a Fellow of the European Academy of Nursing Scholars and a Fellow of the American Academy of Nursing.



A/PROF REBECCA GUY

Associate Professor Rebecca Guy is the Head of the Surveillance, Evaluation and Research Program at the Kirby Institute, University of New South Wales.

She is an epidemiologist with expertise in sexual health public health interventions and surveillance. Her research focuses on reducing the impact of sexually transmissible infections (STIs) in vulnerable populations.

Associate Professor Guy is currently leading large scale studies to evaluate the impact, cost and acceptability of HIV self-testing and STI point-of-care testing and also the population effectiveness of treatment as prevention.

She is one of the chief investigators responsible for establishing a nation-wide surveillance and research network over the past nine years called ACCESS, involving collaboration with over 100 clinics and laboratories.

INVITED SPEAKERS

2016 AUSTRALASIAN HIV & AIDS CONFERENCE



DR JARED BAETEN, MD, PHD

Dr. Baeten is Vice Chair and Professor in the Department of Global Health at the University of Washington. His research focuses on the prevention of HIV-1 and other sexually transmitted diseases, including clinical trials of novel prevention interventions, epidemiologic studies of risk factors for HIV-1 transmission, and biobehavioral and implementation science research aimed at optimizing prevention delivery. He led the Partners PrEP Study and MTN-020/ASPIRE, randomized clinical trials that proved the efficacy of tenofovir-based pills and the dapivirine vaginal ring as pre-exposure prophylaxis (PrEP) against HIV-1 acquisition. Other work includes implementation science projects to deliver antiretroviral treatment and PrEP for HIV-1 prevention and studies exploring use of hormonal contraception as a risk factor for HIV-1.



MS LISA BASTIAN

Lisa Bastian has been the Program Manager of the Western Australian Department of Health's Sexual Health and Blood-borne Virus Program since 2005 and was recently appointed as Manager of the WA HIV Case Management Program. Lisa is responsible for planning and monitoring the HIV policy and public health response in Western Australia. She worked in Aboriginal primary health care and sexual health programs in rural and remote areas in Western Australia for 8 years before working in public health. She is also a member of the Australian Health Protection Principal Committee's Blood-borne Viruses and Sexually Transmissible Infections Subcommittee. She regularly represents the WA Department of Health at national and state-level policy forums.



DR VALERIE DELPECH

Associate Professor Valerie Delpech is a public health consultant based at Public Health England and leads the national surveillance and monitoring of HIV infections and people in HIV care. She trained in medicine and public health in Australia and has worked in communicable diseases control and prevention for over two decades. Valerie is a honorary associate professor at the University College London. Her research interests have focused on better understanding the dynamics of HIV and other STI epidemics and their impact on vulnerable communities. She is a member of research consortia and an expert advisor on national and international committees in relation to HIV surveillance, prevention, and policy and guideline development. Valerie led the writing of the European HIV testing guidelines and chairs the European HIV Testing Week working group. She is an executive trustee for the National AIDS Trust.



DR JOSEPH DOYLE

Dr Doyle is a specialist in infectious diseases and public health medicine, and works at the intersection between clinical medicine, implementation research and health policy. He has particular research interests in epidemiology, prevention and management of blood-borne viruses. He leads a clinical and implementation research program across The Alfred Hospital, Monash University and Burnet Institute to improve treatment access and delivery of hepatitis C treatment. He is currently the co-principal investigator of the HIV/HCV co-infection Eliminate Hepatitis C (co-EC) Study and chief investigator of the NHMRC Eliminate Hepatitis C (EC) Partnership.

He has been an advisor and consultant to the World Health Organisation (WHO) on HIV and viral hepatitis, and led the evidence reviews for first Global WHO guidelines on hepatitis C screening, care and treatment.



MS CINDY LIU

Cindy Liu, M.D., M.P.H., Ph.D., is an Assistant Research Professor in the Department of Environmental and Occupational Health at the George Washington Milken Institute School of Public Health.

The translational goals of her work are to advance our understanding of the role of the microbiome in modifying host susceptibility to pathogens such as HIV, with the goal of leveraging this knowledge to develop novel microbiome-based preventive strategies. Her other research focuses on reducing antibiotic-resistant infections through improving antimicrobial stewardship and the development of rapid diagnostics. Cindy has published more than 30 peer-reviewed manuscripts and she was one of the 2016 ICAAC Young Investigator Award recipients from the American Society for Microbiology.



MS INES LOPES

Ines works as an Executive Director at Estrela Plus. Ines started Estrela Plus in 2009, with four other HIV positive people, to ensure that people living with HIV were a central part of any conversations and decisions that affected their lives. Her long term goal is to see PLHIV in Timor Leste enjoying a normal healthy life, having work and above all access to appropriate treatment, care and support; free from stigma and discrimination.



MS ANGELA KELLY-HANKU

Angela currently heads the Sexual and Reproductive Health Unit at the Papua New Guinea Institute of Medical Research. Angela also holds an appointment in the Public Health Intervention Research Group at the Kirby Institute, UNSW. Angela and her team works closely with the PNG National Department of Health and other in country partner to provide an evidence based response for effective and locally appropriate HIV, sexual and reproductive health policy, programming and health advocacy primarily PNG, but with wider relevance and application to the region.

At present Angela is leading PNG's first Key Population Integrated Bio-Behavioural Survey which includes the use of GeneXpert point of care testing for HIV Viral Load, STIs (genital and anorectal) and TB and is currently being implemented in three major sites.



DR KEDAR NARAYAN

Kedar Narayan is a group leader at the recently opened Center for Molecular Microscopy (CMM) at the Frederick National Laboratory for Cancer Research. Kedar completed his Natural Sciences Tripos from the University of Cambridge, and PhD in Immunology from The Johns Hopkins School of Medicine. At his post-doc at the laboratory of Sriram Subramaniam at NIH, Kedar developed Focused Ion Beam Scanning Electron Microscopy (FIB-SEM) as a high-resolution electron microscopic tool to study HIV-cell interactions, as well as an enabler for chemical imaging. At the CMM, Kedar continues to work with industry partners to develop FIB-SEM applications in biology. In parallel, he collaborates extensively with NIH and other scientists to use nanoscale 3D electron microscopy to investigate various aspects of structural cell biology in health and disease.



A/PROF JAMES WARD

A/Prof James Ward is Head of Infectious Diseases Research- Aboriginal Health at the South Australian Health and Medical Research Institute in Adelaide. He has extensive experience in sexual health and blood borne virus research and is recognised as Australia's expert in the field of STI and BBV control among Aboriginal and Torres Strait Islander people. He has been or is currently a member of a number of professional, technical and expert committees, including the Federal Ministerial Committee on STI and BBV (2011-) NSW Ministerial Advisory Committee STI & HIV (2003-2011), Hepatitis (2003-2009), Victorian HIV Taskforce (2009-2010), Northern Territory Sexual Health Advisory Group (2011-). He is regularly invited to present on his work at national and international conferences, including in 2014 as one of three Australians to be invited as a Plenary Speakers at the International AIDS Conference to be held in Melbourne in July. He is an inaugural Board member of the newly formed Harm Reduction Australia.



10 YEARS OF HPV VACCINATION

SEE HOW FAR WE'VE COME

In Australia, GARDASIL was registered in June 2006.¹

To date, approximately 205 million doses of GARDASIL have been distributed worldwide, including 9 million doses in Australia.²

Real world population impact data in the post vaccination period:

Surveillance to June 2014 shows the proportion of Australian-born women <21 years of age with genital warts decreased from 18.4% in 2004/2005 to 1.1% in 2013/2014 ($p < 0.001$).³

Continued monitoring supports the vaccine's safety profile.⁴

Study design: A retrospective study conducted to investigate the proportion of new patients attending Melbourne Sexual Health Centre (MSHC) who were diagnosed with genital warts between 1 July 2004 and 30 June 2014. A total of 41,776 Australian-born patients were seen for the first time at MSHC during this time, of these 10.2% (4,282) were diagnosed with genital warts. Adjusted ORs were calculated to compare the annual trend in the proportion of patients with genital warts in different risk groups in the pre-vaccination period (before June 2007) and the vaccination period (after July 2007).

PBS Information: This product is listed on the National Immunisation Program (NIP) as part of the school based program. Refer to the NIP Schedule.


Before prescribing, please review the Product Information available at www.Segirus.com.au/PI

GARDASIL® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant vaccine] **INDICATIONS:** GARDASIL is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18 (which are included in the vaccine). GARDASIL is indicated in males aged 9 through 26* years for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18. *Immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations. **CONTRAINDICATIONS:** Hypersensitivity to vaccine, including excipients. **PRECAUTIONS:** Febrile illness, impaired immune response, thrombocytopenia or any coagulation disorder. This vaccine is not intended to be used for active treatment. Routine cervical screening and detection and removal of cervical lesions should be continued in individuals who receive the vaccine. Syncope (fainting) may follow any vaccination, especially in adolescents and young adults. Syncope, sometimes associated with falling, has occurred after vaccination with GARDASIL. Therefore, vaccines should be carefully observed for approximately 15 minutes after administration of GARDASIL. **Use in Pregnancy (Category B2):** GARDASIL is not recommended for use in pregnant women. Use in Lactation: GARDASIL may be administered to lactating women. **ADVERSE REACTIONS:** Injection site (pain, swelling, erythema, bruising, pruritis), headache, fever and very rarely, bronchospasm. **Post-marketing Reports:** The following adverse experiences have been spontaneously reported during post-approval use of GARDASIL. Because these experiences were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or to establish a causal relationship to vaccine exposure. Infections and infestations: cellulitis. Blood and lymphatic system disorders: idiopathic thrombocytopenic purpura, lymphadenopathy. Nervous system disorders: acute disseminated encephalomyelitis, dizziness, Guillain-Barré syndrome, headache, syncope sometimes accompanied by tonic-clonic movements. Gastrointestinal disorders: nausea, vomiting. Musculoskeletal and connective tissue disorders: arthralgia, myalgia. General disorders and administration site conditions: asthenia, chills, fatigue, malaise. Immune system disorders: Hypersensitivity reactions including anaphylactic/anaphylactoid reactions, bronchospasm, and urticaria. **DOSAGE AND ADMINISTRATION:** Administered intramuscularly at day 0 and then at 2 and 6 months after initial dose. In clinical studies, efficacy has been demonstrated in individuals who have received all 3 doses within a 1-year period. Based on TGA approved Product Information. Date of most recent amendment: 4 February 2016.

References: 1. Therapeutic Goods Administration. GARDASIL® Public Summary 2016. 2. Segirus data on file. 3. Chow E *et al.* *Sex Transm Infect* 2015; 91: 214–9. 4. Vichnin M *et al.* *The Pediatric Infectious Disease Journal* 2015; 34(9): 983–991. 5. GARDASIL® Product Information, February 2016. Segirus (Australia) Pty Ltd, ABN 66 120 398 067, 63 Poplar Road, Parkville VIC 3052, distributor for Merck Sharp & Dohme (Australia) Pty Ltd. TM Segirus is a trademark of Segirus UK Limited or its affiliates. © GARDASIL is a registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. Medical Information 1800 642 865. Date of preparation: October 2016. GARD/0616/0024. 13822.



GENERAL INFORMATION



CONFERENCE APP

The Conference App is available to download from all app stores, search for **SHHIV16**.

The conference app is the best way to stay informed during both conferences and free to download. Here's what you can do with the app:

- View the program by time or session, read the abstracts, create your own schedule, make notes and let others know what you think about the session by sharing it on twitter
- Search for speakers you really want to see, read their bio and see what presentations they are giving throughout both conferences
- View a list of all the sponsors and exhibitors and check which booths they are at
- Interact with social media through Twitter and Facebook. Or even send a direct message to that person you've been trying to pin down for a meeting
- Asking questions during presentations has never been made easier. Simply go to the presentation, scroll down to 'Session Engagement' and select 'Ask a Question'

DISCLAIMER

The information in this brochure is correct at the time of printing. The Conference Secretariat reserves the right to change any aspect of the program without notice.

VENUE

Adelaide Convention Centre
North Terrace, Adelaide
South Australia 5000
Australia

T: +61 8 8212 4099

F: +61 8 8212 5101

W: www.adelaidecc.com.au

REGISTRATION DESK

All enquiries should be directed to the registration desk located in the Convention Centre Pre-Function area on the Ground floor and will be open at the following times:

| | |
|-----------------------|-----------------|
| Monday 14 November | 7.00am – 5.30pm |
| Tuesday 15 November | 6.30am – 5.00pm |
| Wednesday 16 November | 6.30am – 5.30pm |
| Thursday 17 November | 8.00am – 5.30pm |
| Friday 18 November | 6.30am – 4.30pm |

SPEAKER PREPARATION ROOM

The speaker preparation room will be located in room L1b on the ground floor.

This room will be open for speakers to load their presentations at the following times:

| | |
|-----------------------|-----------------|
| Monday 14 November | 7.00am – 5.30pm |
| Tuesday 15 November | 6.30am – 5.00pm |
| Wednesday 16 November | 6.30am – 5.30pm |
| Thursday 17 November | 8.00am – 5.30pm |
| Friday 18 November | 6.30am – 4.30pm |

A technician will be available in the speaker preparation room to assist you and to discuss any audio visual queries you may have. You will also have the opportunity to practice your presentation.

All speakers must take their presentation to the speaker preparation room a minimum of **four hours** prior to their presentation or the day before if presenting at a morning session.

If you are not providing slides for your presentation, please advise the AV technician in the speaker preparation room **two hours** prior to your session.

POSTER DISPLAYS

Posters will be displayed for the duration of the conference in the exhibition hall F/G on the ground floor. Posters will be on display during the following times:

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE

MONDAY 14 NOVEMBER 2016

| | |
|--|-------------------|
| Morning tea | 10.55am – 11.30am |
| Lunch | 1.00pm – 2.00pm |
| Psycho-Social Poster Viewing | 2.30pm – 3.30pm |
| Afternoon Tea | 3.30pm – 4.00pm |
| Clinical & Epidemiology Poster Viewing | 5.30pm – 6.30pm |
| Welcome Reception & Poster Viewing | 5.30pm – 6.30pm |

TUESDAY 15 NOVEMBER 2016

| | |
|---|-------------------|
| Morning Tea | 10.30am – 11.00am |
| Lunch | 12.30pm – 1.30pm |
| Health Promotion & Education Poster Viewing | 2.00pm – 3.00pm |
| Afternoon Tea | 3.00pm – 3.30pm |
| Reproductive Health & Sexuality | 4.30pm – 5.00pm |

WEDNESDAY 16 NOVEMBER 2016

| | |
|---------------|-------------------|
| Morning Tea | 10.30am – 11.30am |
| Lunch | 1.00pm – 2.30pm |
| Afternoon Tea | 4.00pm – 4.30pm |

2016 AUSTRALASIAN HIV & AIDS CONFERENCE

WEDNESDAY 16 NOVEMBER 2016

| | |
|---------------|-------------------|
| Morning tea | 10.30am – 11.30am |
| Lunch | 1.00pm – 2.30pm |
| Afternoon Tea | 4.00pm – 4.30pm |

THURSDAY 17 NOVEMBER 2016

| | |
|----------------------------------|-------------------|
| Morning Tea | 10.30am – 11.00am |
| Poster Viewing Highlight Theme C | 12.00pm – 12.30pm |
| Lunch | 12.30pm – 2.00pm |
| Afternoon Tea | 3.30pm – 4.00pm |

FRIDAY 18 NOVEMBER 2016

| | |
|---|-------------------|
| Morning Tea | 10.00am – 10.30am |
| Poster Viewing Highlight Themes B and D | 11.30am – 12.00pm |
| Lunch | 12.00pm – 1.30pm |
| Afternoon Tea | 3.00pm – 3.20pm |

INTERNET HUB & WI-FI

An internet hub is located in the Exhibition Hall F/G on the ground floor. The computers will allow delegates to:

- Complete an online conference evaluation survey
- Print a certificate of attendance
- View the delegate list

Wireless internet is available for the duration of the Conference. Log in details can be obtained from the registration desk.

The internet hub and wireless internet access for the 2016 Australasian HIV&AIDS Conference has been proudly sponsored by BMS.



CATERING

Morning teas, afternoon teas and lunches will be held in the exhibition hall F/G on the ground floor. Dietary requirements noted on your registration form have been passed on to the catering staff.

Vegetarian options will be catered for in the main catering supplied on the buffet. A separate station will be available for other specific dietary requirements such as vegan, halal, gluten intolerance, allergies etc. Please ask the Convention staff at this station for assistance.

At the conference dinner, special dietary requirements such as vegetarian and gluten free meals will only be available for those who have previously advised during the registration process. If you wish to have a vegetarian meal and have not booked one, please see the staff at the Registration Desk by 12.00pm on Monday 15 November.

EMERGENCY AND EVACUATION PROCEDURES

In the event of an emergency, such as a fire, the Convention staff will direct delegates accordingly.

SMOKING

This Conference has a no smoking policy.

MOBILE PHONES/BEEPERS

As a courtesy to all delegates and speakers, please switch off, or set to silent, your mobile phones and beepers during all sessions.

MESSAGES

A message board is situated near the Conference Registration Desk and should be checked regularly.

The Conference Organisers do not accept responsibility for personal mail. Please have all mail sent to your accommodation address.

LUGGAGE STORAGE

Please see the Convention Concierge located at the entrance of the Convention Centre for any luggage store inquiries.

TAXIS

Taxis are readily available from the main entrance of the Convention Centre. The concierge can assist by booking taxis for you.

PARKING

On site car parking is available in the Riverbank and North Terrace in the convention centre. The cost for this facility is \$14.00 Every Day Entry between 5.30am and 9.30am and exit between 2:30pm and 6.30pm. Outside these times casual rates apply up to a maximum of \$26.00 per twenty four hour period. . Payment can be made with cash or credit/debit card*. EFTPOS facilities are not available. * A surcharge is applicable to card payments. Please note this is a public car park and is subject to availability and change.

NAME BADGES

For security purposes, all attendees must wear their name badge at all times while in the Conference venue. If you misplace your name badge, please advise staff at the registration desk.

DELEGATE LIST

Information necessary for your attendance at the Conference will be gathered, stored and disseminated in accordance with the nation's privacy legislation. The delegate list will be viewable by delegates at the Internet Hub which is located in the pre-function area.

EVALUATION SURVEYS

All delegates will be emailed after the Conference with the online survey link. In order to improve the Conference we kindly request your feedback.

LIABILITY/INSURANCE

In the event of industrial disruptions or natural disasters the Conference secretariat cannot accept responsibility for any financial or other losses incurred by delegates. Nor can the Secretariat take responsibility for injury or damage to property or persons occurring during the Conference or associated activities. Insurance is the responsibility of the individual delegate.

ASSOCIATED EVENTS

SOCIAL EVENTS

SEXUAL HEALTH CONFERENCE WELCOME RECEPTION

DATE

Monday 14 November

TIME

5.30pm - 6.30pm

LOCATION

Exhibition Hall in the Adelaide Convention Centre

COST

Complimentary for delegates who have registered for the Sexual Health conference only or joint conferences

Additional Partner/Guest Ticket: AUD66.00

SEXUAL HEALTH CONFERENCE DINNER

DATE

Wednesday 16 November

TIME

7.00pm - 11.00pm

LOCATION

Adelaide Town Hall, 128 King William Street, Adelaide

COST

AUD66.00 for delegate who have registered for the Sexual Health conference or the HIV&AIDS conference or joint conferences

Additional Partner/Guest Ticket: AUD110.00

Join in the fun and get your 'rethinking cap' on for the dinner. There will be a prize for the best hat on the night.

HIV&AIDS CONFERENCE NETWORKING RECEPTION

DATE

Thursday 17 November

TIME

5.30pm - 6.30pm

LOCATION

Exhibition Hall in the Adelaide Convention Centre

COST

Complimentary for delegates who have registered for the HIV&AIDS conference only or joint conferences

Additional Partner/Guest Ticket: AUD66.00

EDUCATIONAL WORKSHOPS AND SATELLITE MEETINGS

MEET THE EXPERTS

DATE

Monday 14 November

TIME

1.00pm - 2.00pm

LOCATION

L2

COST

Complimentary for delegates who have registered for the Sexual Health conference only or joint conferences.

Lunching with the Leaders is a unique opportunity for students and early career researchers/ clinicians to meet with more experienced members of the sexual health community. Several conference delegates with a broad range of practice and research experience will be in attendance at the Lunch. If you are keen to meet some of our sexual health leaders, but have felt too shy to approach them, here is your opportunity! This informal lunch will enable you to discuss research ideas or to seek career or mentoring advice.

ASHNNA BREAKFAST

DATE

Wednesday 16 November

TIME

7.00am - 8.30am

LOCATION

Intercontinental Hotel Adelaide

CASE PRESENTATION BREAKFAST

DATE

Friday 18 November

TIME

7.00am - 8.20am

LOCATION

Riverbank Room 7&8

COST

AUD33.00

BMS SPONSORED SATELLITE: HCV ELIMINATION BY 2026. AUSTRALIA LEADS THE WORLD.

DATE

Wednesday 16 November

TIME

7.00am - 8.30am

LOCATION

Riverbank Room 6/7/8



ASHM HUB

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE | 2016 AUSTRALASIAN HIV & AIDS CONFERENCE

The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) is a peak professional society representing a multidisciplinary health workforce in HIV, viral hepatitis and sexual health. ASHM has a membership of over 1500 and close to 50 organisational members providing reach to a large majority of health care worker activity involved in the sector.

Visit the ASHM Hub — located in the Exhibition Hall — during your attendance at the conference to find out how ASHM can support you in your work. The program below also offers an opportunity to engage + network with ASHM and other colleagues.



ashm

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine

MONDAY 14 NOVEMBER 2016

| | |
|---|---|
| Lunchbreak <i>FROM 1:30 PM</i> | Sexual Health: The Burning Issues An informal session with Infectious Diseases Physicians Dr. Allison Ward and Dr Russell Waddell |
| Afternoon Tea break <i>FROM 3:30 PM</i> | Need tools for management of contact tracing + STI clinical practice? Katy Roy (ASHM HIV + Sexual Health Program Manager) presents two website resources |

TUESDAY 15 NOVEMBER 2016

| | |
|---|--|
| Morning Tea break <i>FROM 10:30 AM</i> | ASHM Continuing Professional Development (CPD) through Online Learning Learn of online learning modules that provide training of STI and BBVs http://lms.ashm.org.au |
| Lunchbreak <i>FROM 12:30 PM</i> | Deadly Sex! A/Prof James Ward (SAHMRI) shares some Deadly Sex insights from this year's congress |
| Afternoon Tea break <i>FROM 3:00 PM</i> | Nurses Social Meet-and-Greet A networking opportunity for Nursing delegates from across Australia and New Zealand |

WEDNESDAY 16 NOVEMBER 2016

| | |
|---|--|
| Morning Tea break <i>FROM 10:30 AM</i> | Combatting BBV and STI-related stigma + discrimination in health care settings ASHM CEO, Levinia Crooks speaks about the work that ASHM is leading in this field |
| Afternoon Tea break <i>FROM 4:00 PM</i> | Sexual transmission of HIV + the law: an Australian medical consensus statement Presented by Paul Kidd (Chair of HIV Legal Working Group of Living Positive Victoria) |

THURSDAY 17 NOVEMBER 2016

| | |
|---|--|
| Morning Tea break <i>FROM 10:30 AM</i> | Increasing uptake of testing + treatment among Priority Populations Presented by ASHM Deputy CEO, Scott McGill and other community representative |
| Lunchbreak <i>FROM 12:30 PM</i> | A lunch time tour of the Asia Pacific - HIV responses in Fiji, Papua New Guinea + more Presented by ASHM's international team, Paul Zulu (PNG) + Dr Dashika Balak (Fiji) |
| Afternoon Tea break <i>FROM 3:30 PM</i> | HIV s100 Prescriber Mixer Mark Boyd (HIV/Infectious Diseases physician) facilitates this networking opportunity |

FRIDAY 18 NOVEMBER 2016

| | |
|---|--|
| Morning Tea break FROM 10.30 AM | Do You DARE? How to conduct an Anal Cancer Examination Dr Jason Ong and Dr Rick Varma demonstrate a DARE (Digital Anal Rectal Examination) |
| Lunchbreak FROM 12:00 PM | Trans men in an innovative HIV response Ted Cook from FTMen-SA speaks about a HIV sexual health campaign highlighting trans MSM |
| | HIV Management in Australasia – Support for Clinical Care Aaron Cogle (Executive Director of NAPWHA) presents <i>Standards for Psychological Support for Adults Living with HIV</i> and the <i>HIV Management in Australasia: A Guide for Clinical Care</i> website |

AFAO COMMUNITY & ADVOCACY HUB 2016

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE | 2016 AUSTRALASIAN HIV & AIDS CONFERENCE

ABOUT AFAO

The Australian Federation of AIDS Organisations (AFAO) is the national federation for the HIV community response. AFAO provides leadership, coordination and support to Australia's policy and advocacy response to HIV. AFAO also works internationally, with a particular focus on Asia and the Pacific.

AFAO's members are the AIDS Councils in each state and territory; the National Association of People With HIV Australia (NAPWHA); the Australian Injecting and Illicit Drug Users League (AIVL); Anwernekenhe National HIV Alliance (ANA); and Scarlet Alliance, Australian Sex Workers Association.

AFAO COMMUNITY AND ADVOCACY HUB 2016

At the 2016 HIV & AIDS conference, AFAO is proud to once again be hosting the AFAO Community and Advocacy Hub. The Hub is a dedicated community space showcasing the work of the AFAO membership and other organisations involved in the HIV community response, through a dynamic program of presentations, panels, Q&A sessions and film screenings.

Visit the Hub in the Exhibition Hall to learn more about current programs and key issues driving Australia's community response to HIV, and to network with staff from AFAO and its member organisations.

The Hub will also be available for community meeting and bookings (contact staff at the Hub for further information).

The full Hub program is available at: <http://bit.ly/afaohub2016>



**THE LONG-AWAITED RESPONSE[†]
IS NOW HERE¹⁻⁵**



DAKLINZA® (DACLATASVIR) IS NOW INDICATED AND PBS LISTED FOR THE TREATMENT OF HIV/HCV CO-INFECTED PATIENTS WITH ANY DEGREE OF CIRRHOSIS^{¥4,5}

DAKLINZA (60 mg) once daily (OD) + sofosbuvir (400 mg) OD treatment for 12 weeks: 97% (123/127) of GT1* patients achieved SVR₁₂[†]; 100% (10/10) of GT3 patients achieved SVR₁₂^{† 2,3}

[†]Cure, or SVR (sustained virologic response) defined as HCV RNA ≤20 IU/mL during treatment and <25 IU/mL 12 weeks post-treatment.^{1,2,3} *GT: genotype.

[¥]DAKLINZA 60 mg OD + sofosbuvir 400 mg OD ± weight-based ribavirin for 12 or 24 weeks.^{4,5}

PBS Information: Authority required for the treatment of Chronic Hepatitis C Infection. Refer to PBS Schedule for full restricted benefit information.

BEFORE PRESCRIBING, PLEASE REVIEW THE FULL PRODUCT INFORMATION. THE APPROVED PRODUCT INFORMATION IS AVAILABLE UPON REQUEST FROM BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD AND CAN BE ACCESSED AT [HTTP://WWW.MEDICINES.ORG.AU/FILES/BQPDAKLI.PDF](http://www.medicines.org.au/files/BQPDAKLI.PDF)

DAKLINZA® MINIMUM PRODUCT INFORMATION.

NAME OF THE MEDICINE: DAKLINZA® (daclatasvir). **INDICATIONS:** In combination with other medicinal products for the treatment of chronic hepatitis C virus infection in adults. **CONTRAINDICATIONS:** Hypersensitivity to DAKLINZA or any component of the product. Co-administration with drugs that strongly induce cytochrome P450 enzyme 3A4 (CYP3A4) may lead to a lower exposure and loss of efficacy of DAKLINZA. Contraindicated drugs include, but are not limited to, phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, dexamethasone and St John's wort. Combination of DAKLINZA with peginterferon alfa and ribavirin in women who are or may become pregnant and men whose female partners are pregnant. **PRECAUTIONS:** Must not be administered as monotherapy. There is potential for drug interaction with amiodarone (Severe bradycardia and heart block have been reported in patients receiving amiodarone with DAKLINZA and sofosbuvir, with or without other medicinal products that lower heart rate. Bradycardia has generally occurred within hours to days. Bradycardia generally resolved after discontinuation of HCV treatment. The mechanism for the bradycardia effect has not been established). Efficacy of DAKLINZA as part of retreatment in patients with prior exposure to a NS5A inhibitor has not been established. Use in lactation is not recommended. Pregnancy Category B3. Use of DAKLINZA with ribavirin: Pregnancy Category X, because of the risks of birth defects and foetal death associated with ribavirin. Refer to the Product Information for a complete list of precautions. **INTERACTIONS WITH OTHER MEDICINES:** Dose adjustment is recommended when co-administered with moderate or strong CYP3A4 inducers (e.g. efavirenz, etravirine, nevirapine) and strong CYP3A4 inhibitors (e.g. clarithromycin, atazanavir, ketoconazole, itraconazole, posaconazole, voriconazole, diltiazem, verapamil). Close monitoring is recommended if amiodarone is administered with DAKLINZA + sofosbuvir. Administration of DAKLINZA may increase systemic exposure to medicinal products that are substrates of P-gp (e.g. digoxin) and organic cation transporter (OCT) 1, OATP 1B1 or 1B3, OCT-1 or BCRP (e.g. rosuvastatin), which could increase or prolong their therapeutic effect and adverse reactions. Caution should be used when DAKLINZA is co-administered with other medicinal products that have a narrow therapeutic range. Refer to the Product Information for a complete list of interactions. **ADVERSE EFFECTS:** In combination with sofosbuvir (with or without ribavirin) the most common adverse events (≥ 10% of patients) were fatigue, headache and nausea. Most adverse events experienced were mild to moderate in severity. The frequencies of adverse reactions commonly associated with ribavirin therapy (rash, cough, anaemia, dyspnoea, insomnia and anxiety) were higher for patients who received ribavirin than for patients who did not. Cardiac arrhythmias including severe bradycardia have been observed in patients receiving amiodarone with DAKLINZA + sofosbuvir. Refer the Product Information for a full list of adverse events. **DOSAGE AND ADMINISTRATION:** The recommended dose of DAKLINZA is 60 mg administered orally once daily for 12 weeks in combination with sofosbuvir for patients with either genotype 1 or genotype 3 HCV. For specific considerations for cirrhotic patients, refer to the Product Information. No dose adjustment of DAKLINZA is required for patients with mild (Child-Pugh A), moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. No dose adjustment of DAKLINZA is required for patients with any degree of renal impairment. Refer to the Product Information for complete dosing recommendations. **PRESENTATION:** 60 mg or 30 mg (daclatasvir dihydrochloride) tablets, available in packs of 28 tablets. Prepared from the Approved Product Information dated 25th August 2016.

References: **1.** Hepatitis C Virus Infection Consensus Statement Working Group. *Australian recommendations for the management of hepatitis C virus infection: a consensus statement 2016*. Melbourne: Gastroenterological Society of Australia, March 2016. Accessible at http://www.gesa.org.au/files/editor_upload/File/PBS%20and%20MBS/Hepatitis%20C%20virus%20infection%20a%20consensus%20statement%202016.pdf, accessed April 2016. **2.** Wyles DL, *et al.* *N Eng J Med*, 2015; 373(8): 714–25. **3.** Wyles DL, *et al.* *N Eng J Med*, 2015; 373(8): Supp App. **4.** Aust Gov't Dept of Health. *Pharmaceutical Benefits Scheme*. Available at <http://www.pbs.gov.au>, accessed August 2016. **5.** DAKLINZA Product Information, 25 August 2016.

© 2016 Bristol-Myers Squibb Company. ®Registered trademark. Daklinza and the Daklinza logo are trademarks of Bristol-Myers Squibb Company. Bristol-Myers Squibb Pharmaceuticals, a Division of Bristol-Myers Squibb Australia Pty Ltd. ABN 33 004 333 322. 4 Nexus Court, Mulgrave, Victoria 3170, Australia. BMS Medical Information: 1800 067 567. Prepared October 2016. BMS3369. DAK/0570/06-16





VENUE FLOOR PLAN

SPEAKERS
PREPARATION
ROOM

MEETING ROOMS


PLENARY

EXHIBITION
/ POSTERS /
CATERING



BREAKOUT
ROOMS

LOCATION MAP



- 1 ADELAIDE CONVENTION CENTRE
- 2 ADELAIDE TOWN HALL
- 3 ROCKFORD ADELAIDE HOTEL
- 4 IBIS STYLES HOTEL
- 5 CROWNE PLAZA HOTEL
- 6 HOTEL GRAND CHANCELLOR HOTEL
- 7 PLAYFORD HOTEL
- 8 OAKS EMBASSY APARTMENTS
- 9 OAKS HORIZON APARTMENTS

EXHIBITION FLOOR PLAN


| | | | | | |
|----|----------|----|--------------------------------------|----|------------------|
| 8 | MSD | 22 | BRISTOL-MYERS SQUIBB | 38 | SPEEDX |
| 10 | FUJIFILM | 24 | GILEAD | 39 | ARCSHS |
| 11 | MSD | 26 | ASHM | 40 | PFIZER |
| 13 | JANSSEN | 28 | ALPHA-PHARM | 41 | TAYLOR & FRANCIS |
| 14 | HOLOGIC | 31 | FOUR SEASONS CONDOMS | | |
| 15 | CEPHEID | 32 | MEDICAL INDUSTRIES | | |
| 16 | ALERE | 35 | SHINE SA | | |
| 19 | SAMESH | 36 | MARIE STOPES INTERNATIONAL/MS HEALTH | | |
| 20 | BAYER | | | | |
| 21 | VIIV | | | | |



CATERING



INTERNET HUB







EXHIBITION DIRECTORY

| BOOTH | COMPANY | COMPANY PROFILE |
|-------|---|---|
| 16 |  | <p>Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™. Alere delivers on this vision by providing reliable and actionable information through rapid diagnostic tests, enhancing clinical and economic health outcomes globally. Over 120 countries use Alere HIV tests including the 4th generation Alere HIV Combo. Other rapid tests include syphilis, hepatitis B and hepatitis C.</p> <p>For more information on Alere, please visit www.alere.com.au.</p> |
| 28 |  | <p>Mylan is one of the world's leading global pharmaceutical companies. Our medicines include generic and brand name products in a variety of dosage forms and therapeutic categories, such as difficult-to-manufacture injectables, transdermal patches and HIV/AIDS antiretroviral (ARV) therapies. The company has innovative research and development capabilities and is one of the world's largest active pharmaceutical ingredient (API) manufacturers. Mylan applies one global quality standard to all of our medications regardless of where they are produced.</p> <p>Mylan is committed to working together with all stakeholders – scientists, healthcare and treatment providers, advocates, policymakers and people living with HIV – to overcome challenges and find solutions that will help:</p> <ul style="list-style-type: none"> • Expand access to treatment • Improve individual health outcomes • Reduce HIV transmission; and • Decrease overall healthcare costs. |
| 39 |  | <p>ARCSSH is a centre for social research into sexuality, health and the social dimensions of human relationships. We work in partnership with communities, community-based organisations, government and professionals to produce research that advances knowledge and promotes positive change in policy, practice and people's lives.</p> |
| 31 |  | <p>Four Seasons Condoms are Australian owned. We started with the aim of producing high-quality condoms that cater for Australian's of all shapes and sizes. We were the first to introduce a range of different sized condoms from Tighter (49mm) to Larger (59mm). We are advocates for the promotion of safe sex and condom research. We proudly support universities, schools, AIDS councils, family planning units and sexual health clinics with their programs for Public Health and sex education</p> |
| 20 |  | <p>Bayer is an innovation company with a more than 150-year history and core competencies in the fields of health care and agriculture. We develop new molecules for use in innovative products and solutions to improve the health of humans, animals and plants. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms.</p> |

| BOOTH | COMPANY | COMPANY PROFILE |
|-------|---|--|
| 22 |  Bristol-Myers Squibb | <p>Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis.</p> <p>Since 2009, we have delivered 12 new products to patients with serious diseases. Four of these are biologic products, including groundbreaking immunotherapies that use the body's immune system to fight cancer. Additional biologic compounds – as well as scores of other investigational medicines – are advancing through the development pipeline. We are recognized as having one of the most productive R&D pipelines in the industry.</p> <p>What sets us apart as a BioPharma leader is our commitment to helping patients prevail over serious diseases and our focus on finding innovative medicines to combat those diseases.</p> <p>Generating new ideas and thinking differently are at the heart of everything we do – making a difference in the lives of patients.</p> |
| 15 |  Cepheid <i>A better way.</i> | <p>Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.</p> |
| 10 |  FUJIFILM <small>Value from Innovation</small> SonoSite | <p>FUJIFILM SonoSite, Inc., the world leader in bedside and point-of-care ultrasound, delivers solutions that meet imaging needs of the medical community. With its VisualSonics ultra high-frequency micro imaging technology, SonoSite continues to influence the future of medical imaging in both the clinical and preclinical markets.</p> <p>Headquartered near Seattle, Washington, USA, the company is represented by subsidiary offices and a global distribution network serving over 100 countries. SonoSite's portable, compact systems are expanding the use of ultrasound across the clinical spectrum by enabling healthcare providers to improve quality of care, physician efficiency, patient safety, patient satisfaction, and reduce costs.</p> <p>For more information, please visit: www.sonosite.com</p> |

| BOOTH | COMPANY | COMPANY PROFILE |
|-------|---|--|
| 24 |  | <p>Gilead's mission is to advance patient care by developing therapeutics to treat life-threatening diseases. We apply biopharmaceutical science to create medicines to treat conditions including Haematology/Oncology (ZYDELIG® [idelalisib]), HIV (GENVOYA® [elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide], STRIBILD® [tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat], EVIPLERA® [tenofovir disoproxil fumarate & emtricitabine & rilpivirine], ATRIPLA® [tenofovir disoproxil fumarate & emtricitabine & efavirenz], TRUVADA® [emtricitabine & tenofovir disoproxil fumarate], EMTRIVA® [emtricitabine], VIREAD® [tenofovir disoproxil fumarate]), chronic hepatitis B (VIREAD® [tenofovir disoproxil fumarate], HEPSERA® [adefovir dipivoxil]), chronic hepatitis C (HARVONI® [ledipasvir & sofosbuvir], SOVALDI® [sofosbuvir]), and systemic fungal infections (AmBisome® [liposomal amphotericin B])</p> |
| 14 |  | <p>Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and molecular solutions, medical imaging systems, and surgical products dedicated to serving the healthcare needs of women and men around the world. Hologic's molecular system, the Panther, provides random access, continuous sample and reagent loading to enable a flexible workflow in your laboratory for STI, HPV and Viral load assays, all on the same platform.</p> <p>In addition, Hologic manufactures and supplies the ThinPrep Pap test, the most widely used liquid-based cytology system with the broadest US FDA claims for cervical screening and out-of-vial testing for HPV and other sexually transmitted infections.</p> |
| 13 |  | <p>Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience and infectious diseases. Driven by its commitment to patients, Janssen brings innovative products, services and solutions to people throughout the world. Janssen-Cilag Pty Ltd is one of the Johnson & Johnson Pharmaceutical Companies.</p> <p>Please visit www.janssen.com/australia for more information.</p> |
| 36 |  | <p>The vision of Marie Stopes International (MSI) is a world in which every birth is wanted. Dr Marie™ and MS Health are part of the MSI global partnership. Our mission of children by choice, not chance drives everything we do. Our Dr Marie™ clinic network provides caring and non-judgemental sexual and reproductive healthcare services to women and men in Australia, including: emergency and long-acting contraception, surgical and medical termination, vasectomy, STI testing, decision-based counselling and 24 hour aftercare. MSI's pharmaceutical operation, MS Health, is a not-for-profit pharmaceutical company that delivers vital reproductive health products and medicines. We continue to develop new strategies and partnerships so we can provide sexual and reproductive health services to as many Australian women and men as possible.</p> |

| BOOTH | COMPANY | COMPANY PROFILE |
|--------|---|---|
| 32 |  | <p>The home of non-hormonal LARC contraception including Copper IUD's TT380 Standard and Short and the LOAD375. The silicone Caya Diaphragm (one size fits most) & Caya gel is a contraceptive gel for use with diaphragm and cervical cap contraceptive methods.</p> <p>We specialise in a broad range of women's health products, including Instruments, Curettes and Point of Care Testing.</p> <p>At this conference we will be introducing the WCG Manual Aspiration kits for early termination and miscarriage.</p> <p>Medical Industries Australia: www.medind.com.au Phone: 0294906200 Email: sales@medind.com.au</p> |
| 8 & 11 |  | <p>Today's MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd-australia.com.au.</p> |
| 40 |  | <p>Working Together for a Healthier World</p> <p>At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world's best-known consumer products.</p> <p>For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.au.</p> |
| 37 |  | <p>SAMESH (South Australian * Mobilisation + Empowerment For Sexual Health) is a joint program of SHine SA and VAC. SAMESH is South Australia's community based, targeted response to HIV and STI health promotion for South Australia. The program delivers a range of services and initiatives, designed to provide the community with information, education, and programs to enhance sexual health and wellbeing. Some of the services provided include counselling, peer support and health promotion targeting gay men, men who have sex with men and people living with HIV or a high risk of HIV. The service is located at 57 Hyde Street Adelaide.</p> |

| BOOTH | COMPANY | COMPANY PROFILE |
|-------|---|---|
| 35 |  | <p>SHine SA is a leading not-for-profit provider of primary care services and education for sexual health and relationship wellbeing.</p> <p>SHine SA provides:</p> <ul style="list-style-type: none"> • Education for teachers, community workers, doctors, nurses and midwives • Clinical training for doctors, nurses and midwives • Testing and treatment across nine clinical sites in South Australia • Free drop-in clinics for people under the age of 30 • Counselling through in-clinic appointments or via telephone • Information and resources through our library, resource centre and website • Health promotion events and community education programs. |
| 38 |  | <p>SpeedX is a privately owned company founded in 2009. Based in Sydney with a subsidiary office in London, SpeedX specialises in innovative multiplex real-time polymerase chain reaction (qPCR) solutions for clinical diagnostics. With CE-IVD multiplex qPCR kits for detection of infectious disease pathogens and antimicrobial resistance markers, SpeedX has a portfolio of market leading detection and priming technologies to enable new healthcare paradigms based on improved delivery and reduced costs. SpeedX has a proven track record of scientific discovery and strives to provide cutting edge clinically relevant tools for the clinical diagnostic market.</p> |
| 41 |  | <p>Taylor & Francis partners with researchers, scholarly societies, universities and libraries worldwide to bring knowledge to life. Our content spans all areas of Humanities, Social Sciences, Behavioural Sciences, Science, Technology and Medicine, and we are one of the world's leading publishers of scholarly journals, books, eBooks, text books and reference works.</p> <p>Our network of offices has grown to include representatives in Oxford, New York, Philadelphia, Boca Raton, Boston, Melbourne, Singapore, Beijing, Tokyo, Kuala Lumpur, Stockholm, New Delhi and Johannesburg. This has enabled Taylor & Francis staff to provide local expertise and support to our editors, societies and authors, as well as tailored, efficient customer service to our library colleagues in institutions around the world.</p> <p>Taylor & Francis Group is an Informa business. Informa is a multinational information provider for the academic, professional and commercial markets with offices in over 40 countries.</p> |
| 21 |  | <p>ViiV Healthcare is the only company 100% focused on HIV, which allows us to make meaningful contributions to people living with or affected by HIV, now and into the future.</p> <p>We do this by delivering innovative treatments and working in partnership with the HIV community and those working to improve the lives of the people living with HIV (PLHIV).</p> <p>We use our knowledge and expertise to ensure there is greater understanding of the needs of PLHIV. ViiV Healthcare knows HIV and has a voice on the issues.</p> |

CONFERENCE PROGRAM **MONDAY 14 NOVEMBER 2016**

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE

MONDAY, 14 NOVEMBER 2016

| | | |
|-------------------|--|---|
| 7.00am | REGISTRATION OPENS | |
| | OPENING PLENARY Room: Hall L Chairs: David Templeton, Meredith Temple-Smith, Carole Khaw and Deborah Bateson | |
| | 8.30am - 8.35am Welcome to Country | |
| | 8.35am - 8.40am Opening of conference by Convenors MEREDITH TEMPLE-SMITH, UNIVERSITY OF MELBOURNE AND CAROLE KHAW, THE ROYAL ADELAIDE HOSPITAL | |
| | 8.40am - 8.45am Welcome Address HON. JACK SNELLING, MINISTER FOR HEALTH, SOUTH AUSTRALIA | |
| 8.30am - 10.55am | 8.45am - 9.05am Opening Address: Discovering Sexual Health KHADIJA GBLA | |
| | 9.05am - 9.25am ASHA Oration ASHA DISTINGUISHED SERVICE Awardee: BASIL DONOVAN, THE KIRBY INSTITUTE, UNIVERSITY OF NEW SOUTH WALES, NSW, AUSTRALIA | |
| | 9.25am - 10.10am Re-thinking HPV and related disease prevention AMBER D'SOUZA, ASSOCIATE PROFESSOR, JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH | |
| | 10.10am - 10.55am The National Cervical Screening Program: On the Cusp of Change MARION SAVILLE, ASSOCIATE PROFESSOR, VICTORIAN CYTOLOGY SERVICE PATHOLOGY, VIC, AUSTRALIA, USA | |
| 10.55am - 11.30am | MORNING TEA Exhibition Hall | |
| | PROFFERED PAPER SESSION 1: CLINICAL SEXUAL HEALTH & EPIDEMIOLOGY Room: Hall L Chairs: Alison Ward and Jayne Lucke | PROFFERED PAPER SESSION 2: PSYCHO-SOCIAL Room: Riverbank Rooms 7 & 8 Chairs: Lyndall Young and Peter Aggleton |
| | 11.30am - 11.45am A Cluster Trial of Molecular Point-Of-Care Tests for Sexually Transmissible Infections (STIs): Treatment Outcomes from Ttango REBECCA GUY | 11.30am - 11.45am Childhood Problem Behaviour and Subsequent Sexual Risk Behaviour: A Prospective Cohort Study JENNIFER MARINO |
| 11.30am - 1.00pm | 11.45am - 12.00pm Direct and Specific Detection of Neisseria Gonorrhoeae Ciprofloxacin Susceptibility—Towards Individualised Treatment ELINA TREMBIZKI | 11.45am - 12.00pm The Lived Experience of Sexual Life with HIV: Thematic Synthesis of Qualitative Research BEN HUNTINGDON |
| | 12.00pm - 12.15pm Efficacy of Pristinamycin for Treatment Resistant Mycoplasma Genitalium CATRIONA BRADSHAW | 12.00pm - 12.15pm Culture Clash? Constructions of Sexual and Reproductive Health from the Perspective of 1.5 Generation Migrants in Australia Using Q Methodology TINASHE DUNE |

MONDAY, 14 NOVEMBER 2016

| | | |
|------------------|---|--|
| 11.30am - 1.00pm | 12.15pm - 12.30pm Should Female Partners of Men with Pathogen Negative Non-Gonococcal Urethritis (NGU) be Informed and Treated? JASON ONG | 12.15pm - 12.30pm Recreational Drug Use among New Zealand Gay and Bisexual Men and it's Association with HIV and STI Risk PETER SAXTON |
| | 12.30pm - 12.45pm Prospective Evaluation of the Resistanceplus™ MG Kit, for the Simultaneous Detection of Mycoplasma Genitalium (MG) and Azithromycin Resistance Mutations LIT YEEN TAN | 12.30pm - 12.45pm Psychological Motivations and Outcomes of Labiaplasty: Quantitative and Qualitative Perspectives GEMMA SHARP |
| | 12.45pm - 1.00pm Microbiological Factors that Contribute to the Development of Incident Bacterial Vaginosis: A Longitudinal Cohort Study GERALD MURRAY | 12.45pm - 1.00pm Understanding Migrants from Burma: Sexual Health Consultations or Deciphering Euphemisms / The Complexities of Sexual Health Communication in Primary Care: Exploring the Needs of Refugees from Burma AMITA TUTEJA |
| 1.00pm - 2.00pm | LUNCH Exhibition Hall | |
| 1.00pm - 2.00pm | LUNCHING WITH THE LEADERS Room L2 | |
| 2.00pm - 3.30pm | PROFFERED PAPER SESSION 3: REPRODUCTIVE HEALTH Room: Riverbank Rooms 7 & 8 Chairs: Kathleen McNamee and Louise Johnson | PROFFERED PAPER SESSION 4: CLINICAL SEXUAL HEALTH & EPIDEMIOLOGY Room: Hall L Chairs: Amber D'Souza and TBC |
| | 2.00pm - 2.15pm Contraception and the Australian Male: A Survey of 2,438 Heterosexual Men Using an Online Dating Site MARY STEWART | 2.00pm - 2.06pm Implementing an Domestic and Aboriginal Family Violence Screening Tool in an Abortion Setting BROOKE CALO |
| | 2.15pm - 2.30pm Intrauterine Devices and Pelvic Inflammatory Disease: Dispelling the Myth AMY MOTEN | 2.06pm - 2.12pm Transguidance SA - A Model for Providing Volunteer Peer Support Services for Transgender and Gender Diverse People and Their Supporters STEPHANIE RUSSELL |
| | 2.30pm - 2.45pm Access, Equity and Costs of Induced Abortion Services in Australia ANGELA TAFT | 2.12pm - 2.18pm Sexuality and Female Genital Mutilation -The Psycho-Social Impact of Sexual Dysfunction due to Female Genital Mutilation KHADIJA GBLA |
| | | 2.18pm - 2.24pm Experience of Domestic Violence Routine Screening in Family Planning NSW Clinics MARY STEWART |

CONFERENCE PROGRAM MONDAY 14 NOVEMBER 2016

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE

MONDAY, 14 NOVEMBER 2016

| | | | |
|-----------------|---|--|--|
| 2.00pm - 3.30pm | 2.45pm - 3.00pm Increasing Access to Medical Termination of Pregnancy through Nurse-Led Models of Care / Decentralising Abortion Services: The Integration of Medical Termination of Pregnancy into a Rural Primary Health Care Setting LAUREN COELLI | 2.45pm - 3.00pm Prevalence of Chlamydia, Gonorrhoea, Syphilis and Trichomonas among Aboriginal and Torres Strait Islander Australians: A Meta-Analysis LUCY WATCHERS-SMITH | 2.24pm - 3.30pm Poster Viewing time |
| | 3.00pm - 3.15pm Access to Medical Abortion in NSW: Insights from Women ELIZABETH SULLIVAN | 3.00pm - 3.15pm Recent Trends in Syphilis in Aboriginal and Torres Strait Islander People and Non-Indigenous Persons in Australia AMY BURROUGHS | |
| | 3.15pm - 3.30pm "They're Not the Evil Thing That We Were Trained to Think They Are": GP Perspectives of Prescribing Intrauterine Contraceptive Devices GABRIELLE LODGE | 3.15pm - 3.30pm An Outbreak of Infectious Syphilis in Northern Australia: The Epidemiology and Public Health Response JOHANNA DUPS | |
| | 3.30pm - 3.45pm Meta-Analysis and Prospective Case Series on the Effectiveness of the Progestin-Only Contraceptives in Management of Hormonally-Sensitive Migraine DEBORAH BATESON | | |
| 3.30pm - 4.00pm | AFTERNOON TEA Exhibition Hall | | |
| 4.00pm - 5.30pm | SYMPOSIUM 1: EDUCATION AND SEXUAL HEALTH: RETHINKING PRACTICE Room: Hall L Chairs: Peter Aggleton and Louise Johnson | SYMPOSIUM 2: MORE ≠ LESS: RETHINKING CONTRACEPTION & ABORTION Room: Riverbank Rooms 7 & 8 Chairs: Deborah Bateson and Kathleen McNamee | JAN EDWARDS TRAINEE SESSION Room: Exhibition Hall Chairs: Damian Conway and David Templeton |
| | 4.00pm - 4.15pm Health and Education: working together for sexual health SARAH THISTLE, FAMILY PLANNING VICTORIA, VIC, AUSTRALIA | 4.00pm - 4.15pm Contraception and Abortion: let's make access easy! PATRICIA MOORE, THE ROYAL WOMEN'S HOSPITAL, AUSTIN HEALTH AND THE ROYAL CHILDREN'S HOSPITAL, MELBOURNE | 4.00pm - 4.15pm Testing for Rectal Chlamydia in Women: Is it Worth it? DANAE KENT |
| | 4.15pm - 4.30pm The Queer Indigenous Body TODD FERNANDO | 4.15pm - 4.20pm Seizing the moment: post-abortion LARC PHILIP GOLDSTONE, MEDICAL DIRECTOR, MARIE STOPES INTERNATIONAL, NSW, AUSTRALIA | 4.15pm - 4.30pm Gonorrhoea Infections of the Rectum, Pharynx and Urethra in Same-Sex Male Partnerships Attending a Sexual Health Service in Melbourne, Australia. VINCENT CORNELISSE |
| | 4.30pm - 4.45pm Responding to the sexual health needs of LGBTIQ young people in Australia: findings from recent research TIFFANY JONES, PRINCIPAL RESEARCHER/ ARC DECRA FELLOW, AUSTRALIAN RESEARCH CENTRE IN SEX HEALTH AND SOCIETY, VIC, AUSTRALIA | 4.20pm - 4.40pm Breaking down barriers: medical abortion via telemedicine in Australia PAUL HYLAND, TABBOT FOUNDATION AND PHILIP GOLDSTONE, MEDICAL DIRECTOR, MARIE STOPES INTERNATIONAL | RAPID FIRE SESSION: CLINICAL SEXUAL HEALTH & EPIDEMIOLOGY 4.30pm - 4.36pm Front-To-Back Wiping and Dabbing Wiping Post-Toilet Significantly Associated With Anal Neoplasia & HR-HPV Carriage in High-Risk Women STEVE SIMPSON JR |

MONDAY, 14 NOVEMBER 2016

| | | | |
|-----------------|--|--|--|
| 4.00pm - 5.30pm | 4.45pm - 5.00pm Best practice delivery of relationships and sexual health education in schools HELEN RAWNSLEY, TEAM LEADER, SHINE SA, AUSTRALIA | 4.40pm - 4.50pm Culture versus choice: key issues for Aboriginal women (a Walgett perspective) CHRISTINE CORBY, CEO, WALGETT ABORIGINAL MEDICAL SERVICE, NSW, AUSTRALIA | 4.36pm - 4.42pm The Changing Pattern of Sexually Transmissible Infection and HIV Diagnoses in New South Wales Publicly-Funded Sexual Health Clinics, 2010-2014 CHRIS BOURNE |
| | | 4.50pm - 5.00pm It needs a rethink! How do we increase LARC uptake in primary care? ANGELA TAFT, JUDITH LUMLEY CENTRE, LA TROBE UNIVERSITY, VIC, AUSTRALIA | 4.42pm - 4.48pm The Molecular Epidemiology of Neisseria Gonorrhoeae in New South Wales, 2012-2014 CAMERON BUCKLEY |
| | 5.00pm - 5.30pm Q&A | 5.00pm - 5.05pm Why aren't Australian young women keen on IUDs? JAYNE LUCKE, AUSTRALIAN RESEARCH CENTRE IN SEX, HEALTH AND SOCIETY, LA TROBE UNIVERSITY, VIC, AUSTRALIA 5.05pm - 5.30pm Panel Discussion | 4.48pm - 4.54pm Injecting Drug Use Is Associated With High Risk Sexual Practices and Sexually Transmissible Infections among Gay Men DENTON CALLANDER 4.54pm - 5.00pm Higher STI Yield among Asymptomatic Gay Men Attending a Community-Based Shop-Front Service Compared with a Fast-Track Sexual Health Clinic Service HEULWEN REES 5.00pm - 5.06pm Is the Increase in Syphilis Cases in Victoria due to Increased Testing? CAROL EL-HAYEK 5.06pm - 5.12pm Gonorrhoea Positivity and Risk Factors among Aboriginal and Non-Aboriginal Women Attending Sexual Health Clinics in Australia LUCY WATCHERS-SMITH 5.12pm - 5.18pm Gonorrhoea among Males (2011-2014) in Victoria, Informed by the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) ANNA WILKINSON 5.18pm - 5.24pm Pro-active Follow-up of Victims of Sexual Assault: An Initiative to Improve Medical Care in Inner Sydney DAVID TEMPLETON |
| 5.30pm - 6.30pm | WELCOME RECEPTION Exhibition Hall | | |

CONFERENCE PROGRAM **TUESDAY 15 NOVEMBER 2016**

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE

TUESDAY, 15 NOVEMBER 2016

| | | |
|-------------------|--|--|
| 6.30am | REGISTRATION | |
| 7.00am - 8.30am | FAMSACA BREAKFAST <i>Room: Riverbank Rooms 7 & 8</i> Breakfast Case Presentations & Discussion | |
| | PLENARY 2 <i>Room: Hall L</i> <i>Chairs: Carole Khaw and Peter Aggleton</i> | |
| 9.00am - 10.30am | Gollow Lecture REBECCA GUY, ASSOCIATE PROFESSOR, THE KIRBY INSTITUTE, UNSW, AUSTRALIA Stronger than the sum of our parts: the importance of a multidisciplinary and integrated approach to sexual health MARK HAYTER, PROFESSOR, UNIVERSITY OF HULL, UK | |
| 10.30am - 11.00am | MORNING TEA Exhibition Hall | |
| | SYMPOSIUM 3: GENDER BASED VIOLENCE: EVERYBODY'S PROBLEM <i>Room: Riverbank Rooms 7 & 8</i> <i>Chairs: Ellie Freedman and Lyndall Young</i> | SYMPOSIUM 4: RETHINKING TESTING AND MANAGEMENT OF SEXUALLY TRANSMISSIBLE INFECTIONS <i>Room: Hall L</i> <i>Chairs: Basil Donovan and David Templeton</i> |
| | 11.00am - 11.20am Community led responses to Aboriginal Family Violence CRAIG RIGNEY, CEO KORNAR WINMIL YUNTI | 11.00am - 11.15am Pharyngeal gonorrhoea - the holy grail? CHRISTOPHER FAIRLEY, MELBOURNE SEXUAL HEALTH CENTRE, ALFRED HEALTH, VIC, AUSTRALIA |
| 11.00am - 12.30pm | 11.20am - 11.35am STI considerations following sexual assault: Prophylaxis, early or late treatment VANITA PAREKH, THE CANBERRA HOSPITAL, ACT, AUSTRALIA | 11.15am - 11.30am Challenges in Mycoplasma genitalium and rectal Chlamydia trachomatis treatment CATRIONA BRADSHAW, SEXUAL HEALTH PHYSICIAN, MELBOURNE SEXUAL HEALTH CENTRE, VIC, AUSTRALIA |
| | 11.35am - 11.50am Technology: Friend or Foe FIONA MORT, DIRECTOR, SOUTH AUSTRALIAN OFFICE FOR WOMEN, SA, AUSTRALIA | 11.30am - 11.45am Patient-delivered partner therapy for STIs: the current state of play in Australia JANE TOMNAY, DIRECTOR, CENTRE FOR EXCELLENCE IN RURAL SEXUAL HEALTH, VIC, AUSTRALIA |
| | 11.50am - 12.10pm Gendered violence and HIV within the multicultural context NAMAM SALIH, WOMEN'S HEALTH PROGRAM COORDINATOR, RELATIONSHIPS AUSTRALIA SA, AUSTRALIA | 11.45am - 12.00pm Sexual transmission of Hepatitis C: who should we be testing and how often? DANIEL RICHARDSON, BRIGHTON & SUSSEX UNIVERSITY HOSPITAL / BRIGHTON & SUSSEX MEDICAL SCHOOL, UK |

TUESDAY, 15 NOVEMBER 2016

| | | | |
|-------------------|---|---|---|
| 11.00am - 12.30pm | 12.10pm - 12.30pm Q&A | 12.00pm - 12.10pm The use of information technology to improve sexual health care CHRISTOPHER FAIRLEY, MELBOURNE SEXUAL HEALTH CENTRE, ALFRED HEALTH, VIC, AUSTRALIA | |
| | 12.10pm - 12.30pm Q&A | | |
| 12.30pm - 1.30pm | LUNCH Exhibition Hall | | |
| 1.30pm - 3.00pm | PROFFERED PAPER SESSION 5: CLINICAL SEXUAL HEALTH & EPIDEMIOLOGY <i>Room: Hall L Chairs: Mark Hayter and Carole Khaw</i> | PROFFERED PAPER SESSION 6: SEXUALITY <i>Room: Riverbank Rooms 7 & 8 Chairs: Graham Nielsen and Sarah Davies</i> | RAPID FIRE SESSION: HEALTH PROMOTION & EDUCATION <i>Room: Exhibition Hall Chairs: Kathleen McNamee and TBC</i> |
| | 1.30pm-1.45pm Chlamydia Control - Where To From Here? Results from the Australian Chlamydia Control Effectiveness Pilot (ACCEPt) MEREDITH TEMPLE-SMITH | 1.30pm - 1.45pm Women Buying Sex in Australia Prompt Rethink of Gendered Sex Industry Narratives HILARY CAULDWELL | 1.30pm - 1.36pm Decentralising Abortion Services. A case study of collaboration in rural Victoria KYLIE STEPHENS |
| | 1.45pm-2.00pm A Chlamydia Diagnosis and Care Cascade for Australian Young People RICHARD GRAY | 1.45pm-2.00pm The Impact of Pornography on Young People's Sexual Lives and Otherwise ANGELA DAVIS | 1.36pm - 1.42pm The Sexy Times Zine: An arts-based, youth-led health promotion resource ALISON COELHO & MIRIAM BAH |
| | 2.00pm - 2.15pm Chlamydia Positivity as a Predictor of Pelvic Inflammatory Disease in Aboriginal and Non-Aboriginal Women: A Population Data Linkage Study JOANNE REEKIE | 2.00pm - 2.15pm Early Sexual Experiences of Heterosexual Teenage Males in Australia: A Cross Sectional Survey REBECCA WIGAN | 1.42pm - 1.48pm Online Rural Sexual Health Education for Health Practitioners: What's important and what's not? SIOBHAN BOURKE |
| | 2.15pm - 2.30pm Likely Impact of Renewal of the Cervical Screening Program in Australia on the Prevalence of Trichomonas Vaginalis: A Modelling Study DAVID REGAN | 2.15pm - 2.30pm Couple Sexual Relationship: When Threesomes Might Not Be Sexy MARIA HART | 1.48pm - 1.54pm No Question Too Awkward: Nurse Nettie, the Online Sexual Health Nurse GEMMA HEARNshaw |
| | 2.30pm-2.45pm Increase in Syphilis Testing and Detection of Early Syphilis among Men Who Have Sex with Men across Australia, 2007-2014 ERIC CHOW | 2.30pm-2.45pm A Regional Advocacy Agenda on Transgender Health Research and Surveillance among Transgender People in the ISEAN Region RAINE CORTES | 1.54pm - 2.00pm Integrating Sexual Health into Youth Early Intervention Mental Health Services LAURA JENKINS |
| 1.30pm - 3.00pm | 2.45pm - 3.00pm The Relationship between Treatment Sensitivity and the Persistence of Gonorrhoea Strains: A Modelling Study BEN HUI | 2.45pm - 3.00pm Q&A | 2.00pm - 3.00pm Poster viewing time |

CONFERENCE PROGRAM **TUESDAY 15 NOVEMBER 2016**

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE

TUESDAY, 15 NOVEMBER 2016

| AFTERNOON TEA EXHIBITION HALL | | | |
|--|---|--|---|
| 3.00pm - 3.30pm | SYMPOSIUM 5: INDIGENOUS SESSION Room: Riverbank Rooms 7 & 8 Chairs: James Ward and Sarah Betts | SYMPOSIUM 6: GP SESSION Room: Hall L Chairs: Michael Burke and Lara Roeske | RAPID FIRE SESSION: SEXUALITY & REPRODUCTIVE HEALTH Room: Exhibition Hall Chairs: Chris Fox and Amy Moten |
| | 3.30pm - 3.55pm STRIVE Study JAMES WARD, HEAD INFECTIOUS DISEASES ABORIGINAL HEALTH, SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE, SA, AUSTRALIA | 3.30pm - 3.45pm Rising Australian epidemics: Gonorrhoea and Syphilis - what is the role of the General Practitioner? JJASON ONG, SEXUAL HEALTH PHYSICIAN, MONASH UNIVERSITY, THE ALFRED - MELBOURNE SEXUAL HEALTH CENTRE, VIC, AUSTRALIA | 3.30pm - 3.36pm MTOP ONE STOP SHOP - Implementing a Medication Abortion Training Model in a Community Based Reproductive and Sexual Health Service CHRISTINA INNESS |
| 3.30pm - 5.00pm | 3.30pm - 4.00pm Emergency contraception in the Australian setting: introducing a new oral alternative DEBORAH BATESON, MEDICAL DIRECTOR, FAMILY PLANNING NSW, AUSTRALIA | 3.45pm - 4.10pm Sexual Health Services - Western Sydney Youth's preferred site of care for sexual health MICHAEL BURKE AND MEDICAL STUDENT | 3.36pm - 3.42pm Pregnancy Recurrence and Complications after Terminations: An Audit of Abortions in South Australia WILLIAM BREIDAHN |
| | 3.55pm - 4.10pm Variation in Sexual Health Care Delivery at Primary Health Care Level in Australia: Findings from the Audit and Best Practice for Chronic Disease Projects BARBARA NATTABI, SENIOR LECTURER, WESTERN AUSTRALIA CENTRE FOR RURAL HEALTH, UNIVERSITY OF WESTERN AUSTRALIA | 4.00pm - 4.25pm Mycoplasma Genitalium - Is this the "New Chlamydia?" CATRIONA BRADSHAW, SEXUAL HEALTH PHYSICIAN, MELBOURNE SEXUAL HEALTH CENTRE, ALFRED HOSPITAL; ASSOCIATE PROFESSOR, MONASH UNIVERSITY, VIC, AUSTRALIA | 3.42pm - 3.48pm The Impact of Abortion Attitudes and Stigma on Access in Developed Countries: Findings of a Systematic Review KARI VALLURY |
| | 4.10pm - 4.25pm An Interim Evaluation of Outbreak Response Effectiveness to Control the Syphilis Outbreak in the Northern Territory, 2014-2016 LINDA GARTON, REMOTE SEXUAL HEALTH PROGRAM MANAGER, NT DEPARTMENT OF HEALTH, NT, AUSTRALIA | 4.25pm - 4.35pm A Crash course in HIV pre-exposure prophylaxis (PrEP) for GPs VINCENT CORNELISSE, MELBOURNE SEXUAL HEALTH CENTRE, MONASH UNIVERSITY, VIC, AUSTRALIA | 3.48pm - 3.54pm A Changing Sexual Landscape of Gay Asian Men in Sydney: Implications for HIV/STI Prevention. TIM CHEN |
| | 4.25pm - 4.35pm Methamphetamine, sexual health knowledge and attitudes among Aboriginal and Torres Strait Islander young people: Results from the GOANNA survey DANIEL DIFIORE, HONORS STUDENT, SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE, SA, AUSTRALIA | | 3.54pm - 4.00pm Porn. What Are Young People Actually Watching? ANGELA DAVIS |

TUESDAY, 15 NOVEMBER 2016

| | | | |
|-----------------|---|--|--|
| 3.30pm - 5.00pm | 4.35pm - 4.55pm The importance of Community Development, "A Bottoms Up Approach" GRACELYN SMALLWOOD, PROFESSOR, JAMES COOK UNIVERSITY, QUEENSLAND, AUSTRALIA | 4.35pm - 4.50pm 10 key practical implications of the Renewed National Cervical Screening Programme for GPs and practice teams. SIOBHAN BOURKE | 4.00pm - 4.06pm Sex Life of HIV Positive Gay Men and HIV Negative Gay Men at Balimedika MADE YOGI OKTAVIAN PRASETIA |
| | 4.55pm - 5.05pm Presentation TBC | 4.50pm - 5.00pm Q&A | 4.06pm - 4.12pm The Initiative for Multipurpose Prevention Technologies (IMPT): Building the Movement DEBORAH BATESON |
| | | | 4.12pm - 5.00pm Poster viewing time |

CONFERENCE PROGRAM **WEDNESDAY 16 NOVEMBER 2016**

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE | 2016 AUSTRALASIAN HIV & AIDS CONFERENCE

WEDNESDAY, 16 NOVEMBER 2016

| 6.30am | REGISTRATION OPENS | |
|-------------------|---|---|
| 7.00am - 8.30am | 7.00am - 8.30am BMS PLATINUM SPONSORED SATELLITE HCV ELIMINATION BY 2026. AUSTRALIA LEADS THE WORLD Room: Riverbank Rooms 7 & 8 Chair: Norman Swan | 7.30am - 8.30am ASHHNA BREAKFAST (OFFSITE) Room: Offsite: Intercontinental Adelaide |
| 7.00am - 8.30am | ASHM OPENING PLENARY: HIV PREVENTION Room: Hall L Chairs: Steve Wesselingh and Levinia Crooks | SYMPOSIUM 7: SEXUALITY Room: Riverbank Room 6 Chairs: Graham Neilsen and Sarah Davies |
| 8.45am - 9.00am | 8.45am - 9.00am Welcome to land speaker Health Minister Conference welcome | 9.00am - 9.20am What can we learn from pornography? ALAN MCKEE, PROFESSOR, UNIVERSITY OF TECHNOLOGY SYDNEY, NSW, AUSTRALIA |
| 8.45am - 10.30am | 9.00am - 9.30am As predicted divergence is happening; HIV in Aboriginal and Torres Strait Islander communities JAMES WARD, HEAD INFECTIOUS DISEASES ABORIGINAL HEALTH, SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE, SA, AUSTRALIA | 9.20am - 9.40am Young kids and gender identity. What is WHO playing at? SAM WINTER, AUSTRALIA |
| | 9.30am - 10.00am PrEP at age 6 JARED BAETEN, VICE CHAIR AND PROFESSOR, UNIVERSITY OF WASHINGTON, USA | 9.40am - 10.00am Trans Health Matters KRISTYANA FINCH |
| | 10.00am - 10.30am Penile microbiome and HIV susceptibility CINDY LIU, ASSISTANT RESEARCH PROFESSOR, GEORGE WASHINGTON MILKEN INSTITUTE SCHOOL OF PUBLIC HEALTH, USA | 10.00am - 10.30am Panel Discussion |
| 10.30am - 11.30am | MORNING TEA Exhibition Hall | |
| 10.40am - 11.20am | KIRBY & CSRH SURVEILLANCE REPORTS INFO SESSION Riverbank Rooms 7 & 8 | |

WEDNESDAY, 16 NOVEMBER 2016

| | | | |
|------------------|---|---|---|
| 11.30am - 1.00pm | <p>SYMPOSIUM SESSION: ASHM THEME A/B CROSS TRACK WHERE ARE WE WITH THE CURE: SCIENCE, TRIALS AND COMMUNITY</p> <p>Room: Riverbank Rooms 7 & 8 Chairs: Michelle Hagenauer and Damian Purcell</p> <p>11.30am - 12.00pm What is the Science Telling Us? ANTHONY KELLEHER, KIRBY INSTITUTE, NSW, AUSTRALIA</p> | <p>JOINT SYMPOSIUM SESSION: PREVENTION OF ANAL CANCER IN GAY AND BISEXUAL MEN: THE CURRENT STATE-OF-PLAY AND FUTURE DIRECTIONS</p> <p>Room: Hall L Chairs: Richard Hillman and Craig Cooper</p> <p>11.30am - 11.45am The epidemiology of anal HPV and anal cancer AMBER D'SOUZA, ASSOCIATE PROFESSOR, JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH, USA</p> | <p>PROFFERED PAPER SESSION: EDUCATION AND HEALTH PROMOTION</p> <p>Room: Riverbank Room 6 Chairs: Peter Aggleton and Sarah Thistle</p> <p>11.30am - 11.45am Sexual Behaviours and Tinder Usage among Young Australians CAITLIN DOUGLASS</p> |
| | <p>11.45am - 12.00pm What should we be doing for our patients now? JASON ONG, MONASH UNIVERSITY, THE ALFRED - MELBOURNE SEXUAL HEALTH CENTRE, VIC, AUSTRALIA</p> | <p>11.45am - 12.00pm Music Settings for the Sexual Health Promotion of Young People - Online and Offline GEMMA HEARNshaw</p> | |
| | <p>12.00pm - 12.30pm What do the Clinical trials and cohorts tell us? JAMES MCMAHON, ALFRED HEALTH AND MONASH UNIVERSITY, VIC, AUSTRALIA</p> | <p>12.00pm - 12.15pm An update from the Study for the Prevention of Anal Cancer (SPANC), RPA Sexual Health, Sydney Local Health District, NSW, Australia DAVID TEMPLETON</p> | <p>12.00pm - 12.15pm Sexual Health Promotion and STI Prevention on the Margins: Kink, BDSM, and Sexually Adventurous Women VIV MCGREGOR</p> |
| | <p>12.30pm - 1.00pm What's in it for me? - Balancing hope and healthy scepticism about HIV cure research BRENT ALLAN, EXECUTIVE OFFICER, LIVING POSITIVE VICTORIA, AUSTRALIA</p> | <p>12.15pm - 12.25pm Educating the community about HPV and anal cancer BEN WILCOX, AUSTRALIAN FEDERATION OF AIDS ORGANISATIONS, NSW, AUSTRALIA</p> | <p>12.15pm - 12.30pm Sexual Health and Relationships Education (Share) - A Comic Based Resource for Young People from Refugee and Migrant Backgrounds ALISON COELHO & MIRIAM BAH</p> |
| 1.00pm - 2.30pm | <p>LUNCH Exhibition Hall</p> | <p>12.25pm - 12.35pm A community perspective on anal cancer and anal HPV LANCE FEENEY, POSITIVE LIFE NSW, AUSTRALIA</p> | <p>12.30pm - 12.45pm La Perouse Panthers Knock Out Project KEVIN HEATH AND JULIA PURCHAS</p> |
| | | <p>12.35pm - 12.40pm Living through the diagnosis and treatment of anal cancer BRAD ATKINS</p> | <p>12.45pm - 1.00pm Relationships and Sexual Health Curriculum in Action CHERYL PEAT</p> |

CONFERENCE PROGRAM **WEDNESDAY 16 NOVEMBER 2016**

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE | 2016 AUSTRALASIAN HIV & AIDS CONFERENCE

WEDNESDAY, 16 NOVEMBER 2016

| ASHM AGM Riverbank Room 6 | | | |
|------------------------------|--|--|--|
| 1.30pm - 2.15pm | <p>SYMPOSIUM SESSION:</p> <p>ETHICAL CONSIDERATIONS IN TREATMENT CULTURE: WHEN PUSH COMES TO SHOVE</p> <p>Room: Riverbank Rooms 7&8 Chairs: Bridget Haire and Susan Kippax</p> | <p>JOINT SYMPOSIUM SESSION:</p> <p>PREP IMPLEMENTATION, EXPERIENCE AND IMPACT</p> <p>Room: Hall L Chair: Martin Holt and David Templeton</p> | <p>SYMPOSIUM 8:</p> <p>THE OTHER SIDE OF THE REPRODUCTIVE COIN: FERTILITY, CONCEPTION AND OUTCOMES</p> <p>Room: Riverbank Room 6 Chairs: Louise Johnson and Karen Hammarberg</p> |
| | <p>2.30pm - 2.45pm</p> <p>"You have HIV and you must start treatment today" - how urgent is the need to start?</p> <p>JENNIFER HOY, PROFESSOR DIRECTOR, HIV MEDICINE, ALFRED HOSPITAL AND MONASH UNIVERSITY, VIC, AUSTRALIA</p> | <p>2.30pm - 2.45pm</p> <p>It's taken a village: PrEP in Victoria</p> <p>EDWINA WRIGHT, INFECTIOUS DISEASES SPECIALIST, ALFRED HEALTH, VIC, AUSTRALIA</p> | <p>2.30pm - 2.45pm</p> <p>Clinical perspectives and research related to advanced parental age and other factors impacting on fertility, conception and reproductive outcomes. What does that mean for women, men and the next generation?</p> <p>LOUISE HULL, CLINICIAN, FERTILITY SA/THE UNIVERSITY OF ADELAIDE, SA, AUSTRALIA</p> |
| 2.30pm - 4.00pm | <p>2.45pm - 3.00pm</p> <p>Holding space for those who hold doubts</p> <p>CHRISTY NEWMAN, SENIOR RESEARCH FELLOW, CENTRE FOR SOCIAL RESEARCH IN HEALTH, UNSW AUSTRALIA</p> | <p>2.45pm - 3.00pm</p> <p>Targeted implementation of PrEP in NSW</p> <p>IRYNA ZABLOTSKA-MANOS, THE KIRBY INSTITUTE, UNSW, AUSTRALIA</p> | <p>2.45pm - 3.00pm</p> <p>When forming a family is desired. Fertility decision making and family circumstances. Research into why women opt to freeze their eggs and impact of a lack of partner during the fertile years</p> <p>JANE FISHER, JEAN HAILES PROFESSOR OF WOMEN'S HEALTH AND DIRECTOR JEAN HAILES RESEARCH UNIT, MONASH UNIVERSITY, VIC, AUSTRALIA</p> |
| | <p>3.00pm - 3.20pm</p> <p>Treatment in the context of public health risk</p> <p>ANNA MCNULTY, DIRECTOR, SYDNEY SEXUAL HEALTH CENTRE, NSW, AUSTRALIA</p> | <p>3.00pm - 3.20pm</p> <p>PrEP in the USA: learning by doing</p> <p>JARED BAETEN, VICE CHAIR AND PROFESSOR, UNIVERSITY OF WASHINGTON, USA</p> | <p>3.00pm - 3.15pm</p> <p>Presentation of findings from a pilot research based in Walgett related to family building aspirations, barriers and enablers</p> <p>CHRISTINE CORBY, CEO, WALGETT ABORIGINAL MEDICAL SERVICE, NSW, AUSTRALIA</p> |
| | <p>3.20pm - 3.35pm</p> <p>The Empowered Patient</p> <p>LANCE FEENEY, POSITIVE LIFE NSW, AUSTRALIA</p> | <p>3.20pm - 3.35pm</p> <p>The changing experiences of negotiating sex with (potential) partners for men using PrEP</p> <p>DEAN MURPHY, RESEARCH FELLOW, CENTRE FOR SOCIAL RESEARCH IN HEALTH, UNSW, AUSTRALIA</p> | <p>3.15pm - 3.30pm</p> <p>Barriers and enablers, men and reproductive role in childbearing decision, implications for public education</p> <p>ROB MCLACHLAN, PRINCIPAL RESEARCH FELLOW; ENDOCRINOLOGIST, MONASH MEDICAL CENTRE, VIC, AUSTRALIA</p> |

WEDNESDAY, 16 NOVEMBER 2016

| | | | | | |
|---------------------|---|---|--|--|--|
| | 3.35pm - 3.50pm Treatment -as-prevention: The impact on clients DANNY BARNES, SENIOR SOCIAL WORKER, POSITIVE CENTRAL (COMMUNITY HIV ALLIED HEALTH TEAM), NSW, AUSTRALIA | 3.35pm - 3.50pm Do we have the courage and ambition to end HIV in Australia? Examining our progress and prospects through the case of PrEP DARRYL O'DONNELL, AUSTRALIAN FEDERATION OF AIDS ORGANISATIONS, AUSTRALIA | 3.30pm - 3.45pm Sleepwalking into infertility: the need for a public health approach toward advanced maternal age. Better sex education for young people is a public health solution to the problem of maternal age JAYNE LUCKE, AUSTRALIAN RESEARCH CENTRE IN SEX, HEALTH AND SOCIETY, LA TROBE UNIVERSITY, VIC, AUSTRALIA | | |
| | 3.50pm - 4.00pm Q&A | 3.50pm - 4.00pm Q&A | 3.45pm - 4.00pm Panel Discussion | | |
| 4.00pm - 4.30pm | AFTERNOON TEA Exhibition Hall | | | | |
| | SYMPOSIUM SESSION: BASIC SCIENCE - MICROBIOME - SYNERGIES OF PATHOGENS <i>Room: Riverbank Rooms 7&8</i> <i>Chairs: Steve Wesselingh and TBC</i> | | | | |
| 4.30pm - 5.30pm | 4.30pm - 5.00pm Antimicrobial and Immune Modulatory Effects of Vaginal Microbiota Acid Metabolites and HIV Susceptibility GILDA TACHEDJIAN, ASSOCIATE PROFESSOR, BURNET INSTITUTE, VIC, AUSTRALIA | SEXUAL HEALTH CONFERENCE PLENARY 3 <i>Room: Hall L</i> <i>Chair: Chris Bourne</i> | SEXUAL HEALTH CONFERENCE CLOSING CEREMONY <i>Room: Hall L</i> <i>Chairs: Deborah Bateson, Meredith Temple-Smith and Carole Khaw</i> | | |
| | 5.00pm - 5.30pm Title TBC CINDY LIU, ASSISTANT RESEARCH PROFESSOR, GEORGE WASHINGTON MILKEN INSTITUTE SCHOOL OF PUBLIC HEALTH, USA | | | | |
| 4.00pm - 6.00pm | NAPWHA Satellite Symposium - Positive Action Community Grants Exhibition Hall | | | | |
| 7.00pm - 11.00pm | SEXUAL HEALTH CONFERENCE DINNER Adelaide Town Hall | | | | |
| | | 5.00pm - 5.30pm Formalities/Prizes/Handover to 2017 Convenor | | | |

CONFERENCE PROGRAM THURSDAY 17 NOVEMBER 2016

2016 AUSTRALASIAN HIV & AIDS CONFERENCE

THURSDAY, 17 NOVEMBER 2016

| | | | | | |
|-------------------|---|---|---|--|--|
| 8.00am | REGISTRATION OPENS | | | | |
| 9.00am - 10.30am | PLENARY 2 Room: Hall L Chairs: <i>Levinia Crooks and Mark Boyd</i> | | | | |
| | 9.00am - 9.30am Mind the gap: Progress towards treatment for all and its impact on prevention VALERIE DELPECH, PUBLIC HEALTH CONSULTANT, PUBLIC HEALTH ENGLAND, UK 9.30am - 10.00am Past. Present. Future: Responding to HIV in Papua New Guinea ANGELA KELLY-HANKU, SEXUAL AND REPRODUCTIVE HEALTH UNIT, PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH, PAPUA NEW GUINEA 10.00am - 10.30am Keynote 6 - What do we need to better understand the needs of mobile and migrant populations in Australia? Is a national response achievable? LISA BASTIAN, PROGRAM MANAGER, WESTERN AUSTRALIAN DEPARTMENT OF HEALTH, WA, AUSTRALIA | | | | |
| 10.30am - 11.30am | MORNING TEA Exhibition Hall | | | | |
| | CONCURRENT 1: THEME A PROFFERED PAPER LATE BREAKER SESSION Room: Riverbank Room 8 Chairs: Kieran Cashin and Renee Van Der Sluis | CONCURRENT 2: THEME B PROFFERED PAPERS INCREASING THE DEMAND FOR HIV TESTING Room: Hall L Chairs: Kim Wilson | CONCURRENT 3: THEME C PROFFERED PAPERS TREATMENT AS PREVENTION Room: Riverbank Room 6 Chairs: Mark Stooove and Jennifer Power | CONCURRENT 4: THEME D PROFFERED PAPERS RESPONDING TO A CHANGING HIV EPIDEMIC Room: Riverbank Room 7 Chairs: Christy Newman and Colin Batrouney | CONCURRENT 5: ABORIGINAL AND TORRES STRAIT ISLANDER SYMPOSIUM - 90/90/90 BUT WHO ARE THE 10/10/10? Room: Riverbank Room 8 Chairs: Gracelyn Smallwood and James Ward |
| 11.00am - 12.30pm | 11.00am - 11.15am Rectal CD4+ T-cells that express CCR6 are associated with HIV persistence in HIV-infected individuals on antiretroviral therapy JENNY ANDERSON | 11.00am - 11.15am Innovative ways to improve the demand for testing - update on the technology and review of programs and novel implementation opportunities PHILIP CUNNINGHAM AND MARK STOOVE | 11.00am - 11.15am Earlier Initiation of Antiretroviral Therapy in a National Cohort of People Newly Diagnosed With HIV Attending Australian Sexual Health Clinics HAMISH MCMANUS | 11.00am - 11.15am Demonstrating the Value of Community-Control in Australia's Response to HIV DARRYL O'DONNELL | 11.00am - 11.05am Evidence of divergence in HIV rates in Aboriginal and Torres Strait Islander communities; Making sure no-one is left behind in the Australian response JAMES WARD |
| | 11.15am - 11.30am Examining the Role of Human Dendritic Cells in Mediating Sexual Transmission of HIV ANDREW HARMAN | 11.15am - 11.30am Trends in Viral Suppression among People Living with HIV in Victoria, 2009-2014 JASON ASSELIN | 11.15am - 11.30am Local Qualitative Research on the Sexual Behaviour of Gay & Bisexual Men Needed to Help End HIV JOHANN KOLSTEE | 11.05am - 12.30pm Panel discussion - How do we ensure that Aboriginal and Torres Strait Islander communities are not the 10/10/10? JAMES WARD, GRACELYN SMALLWOOD, MARK STOOVE, DARREN RUSSELL, MICHAEL LARKIN, DAVID JOHNSON AND NEVILLE FAZULLA | |

THURSDAY, 17 NOVEMBER 2016

| | | | | | |
|-------------------|--|--|---|---|------------------------|
| 11.00am - 12.30pm | 11.30am - 11.45am Novel HIV-1 glycoprotein vaccine with enhanced exposure of broad neutralization epitopes ANDY POUMBOURIOUS | 11.30am - 11.45am a[TEST] Oxford Street: A Successful Model of Community Rapid HIV Testing in Sydney / Effect of an Express Testing Service for Gay and Bisexual Men on HIV Testing Frequency in Sydney VICKIE KNIGHT | 11.30am - 11.45am Perception of Treatment as Prevention among HIV-Positive Gay Men with Sustained Viral Suppression LIMIN MAO | 11.30am - 11.45am Strategies to Improve Treatment Uptake for People with HIV in NSW HEATHER-MARIE SCHMIDT | Panel discussion cont. |
| | 11.45am - 12.00pm HIV vaccine-induced protective antibodies: lessons from the sacred cow DAMIAN PURCELL | 11.45am - 12.00pm Will a Guiding Poster be a Sustainable Intervention in Improving Provider Initiated HIV Testing (PIHT) At Healthcare Settings? PRAGEETH SURANGA PREMADASA | 11.45am - 12.00pm Enhancing HIV surveillance to track performance against the targets of the New South Wales HIV Strategies 2012-2015 and 2016-2020 CHRISTINE SELVEY | 11.45am - 12.00pm Home Insemination and HIV Prevention among Same-Sex Attracted Communities in Victoria JEN JOHNSON | |
| | 12.00pm - 12.15pm High-throughput analysis of vaccine-induced antibody-dependent effector functions against HIV-1 MILLA MACLEAN | 12.00pm - 12.15pm Doctors' Current Practice and Perceived Barriers to HIV Testing in the Emergency Department in Australia LYDIA JONES | 12.00pm - 12.05pm Post-Exposure Prophylaxis for HIV - What Else to Consider? KATY ROY | 12.00pm - 12.15pm "I had to be someone new, to start afresh": residential mobility of people living with HIV to regional Queensland. / 'HIV is the least of my worries': syndemic suffering in people living with HIV in regional Queensland Australia LISA FITZGERALD | |
| | 12.15pm - 12.30pm Resolution of Cell to Cell Spread of HIV STUART TURVILLE | 12.15pm - 12.30pm Predictors of HIV Status Disclosure among Sample of Recently HIV-Diagnosed Gay Men in Australia IAN DOWN | 12.05pm - 12.10pm How did you hear about us? Characterising men by the method they found out about a new HIV testing service KATHLEEN RYAN 12.10pm - 12.15pm HIV "Not Further Specified": The Limitations in Classifying and Reporting Heterosexual Exposure to HIV CLARISSA MOREIRA 12.15pm - 12.30pm Poster Viewing Highlight Theme C | 12.15pm - 12.30pm Negotiating Trust, Struggling for Control: Everyday Narratives of Unwanted Disclosure of HIV Status among People Living With HIV in Australia PETER AGGLETON | |

CONFERENCE PROGRAM THURSDAY 17 NOVEMBER 2016

2016 AUSTRALASIAN HIV & AIDS CONFERENCE

THURSDAY, 17 NOVEMBER 2016

| 12.30pm - 2.00pm | LUNCH Exhibition Hall | CONCURRENT 6: THEME A PROFFERED PAPER HIV PERSISTENCE AND LATENCY | CONCURRENT 7: THEME B PROFFERED PAPER CASCADE OF HIV CARE | CONCURRENT 8: THEME C PROFFERED PAPERS EPIDEMIOLOGY AND SURVEILLANCE OF DIVERSIFYING EPIDEMICS | CONCURRENT 9: THEME D SYMPOSIUM REGIONAL/ DOMESTIC RESPONSES (CHANGING FUNDING LANDSCAPE) | CONCURRENT 10: SPONSORED SATELLITE MEASURING THE SUCCESS OF THE NSW HIV STRATEGY - ON THE ROAD TO VIRTUALLY ELIMINATING HIV TRANSMISSION BY 2020? |
|------------------|---|--|---|--|--|--|
| | Room: Riverbank Room 8 Chairs: Jenny Anderson and TBC | Room: Hall L Chairs: Rob Finlayson and Anna Wilkinson | Room: Riverbank Room 6 Chairs: Danny Gallant and Lisa Bastian | Room: Riverbank Room 7 Chairs: Levinia Crooks and Angela Kelly-Hanku | Room: Riverbank Room 5 Chairs: Christine Selvey and Andrew Grulich | |
| 2.00pm - 3.30pm | 2.00pm - 2.15pm Memory CD4+ T Cells Expressing HLA-DR Contribute to HIV Persistence during Prolonged ART EUNOK LEE | 2.00pm - 2.15pm Comparing HIV Viral Load and CD4 counts for people retained in care to people with unknown outcomes JAMES MCMAHON | 2.00pm - 2.15pm Recent trends in new diagnoses of HIV in NSW residents, 2011-2015, who report heterosexual acquisition of HIV MEREDITH WICKENS | 2.00pm - 2.10pm The Global fund context BILL BOWTELL | 2.00pm - 2.10pm NSW HIV Strategy, Community Mobilisation and Attitudes to Treatment as Prevention TasP JOANNE HOLDEN AND KAREN PRICE | |
| | 2.15pm - 2.30pm IFNa Activates Latent HIV-1 in Non-Proliferating Latently Infected T-Cells RENEE VAN DER SLUIS | 2.15pm - 2.30pm Women, those who inject drugs, and younger people more likely to have 'detectable' viral loads DENTON CALLANDER | 2.15pm - 2.30pm HIV in People Born Overseas, Australia, 2005-2014; a Changing Epidemiology PRAVEENA GUNARATNAM | 2.10pm - 2.20pm Working in an environment of change Jules Kim: A perspective from a peer-based sex worker organisation TBC | 2.10pm - 2.15pm NSW HIV Prevention Partnership Project ANDREW GRULICH | |
| | 2.30pm - 2.45pm Sustained increase in cell associated HIV RNA following short course vorinostat in HIV-infected individuals on antiretroviral therapy TALIA MOTA | 2.30pm - 2.45pm The Effect of Combination Antiretroviral Therapy (cART) on Life Expectancy in Thailand using the National Health Security Office Database (NHSO) SIRINYA TEERANANCHAI | 2.30pm - 2.45pm Prevention of mother-to- child transmission of HIV in Australia: An analysis of 30 years of national surveillance data SKYE MCGREGOR | 2.20pm - 2.30pm Regional Responses to HIV - the importance of strengthening civil society for successful responses DARRYL O'DONNELL | 2.15pm - 2.20pm HIV Notifications CHRISTINE SELVEY | |
| | | | | 2.30pm - 2.40pm Money Up Front! Challenges to Resourcing Peer-Led Responses to Maintain Successes and Continue to Meet the Needs of Sex Workers JULES KIM | 2.20pm - 2.30pm HIV testing TIMOTHY DUCK | |

THURSDAY, 17 NOVEMBER 2016

| | | | | | |
|-----------------|--|---|--|---|---|
| 2.00pm - 3.30pm | 2.45pm - 3.00pm Dynamics of Reactivation from Latency in SIVmac239m Infected Macaques MYKOLA PINKEYVYCH | 2.45pm - 3.00pm Trends of CD4 response among Asian HIV-positive patients initiating Antiretroviral Therapy in 2003-2013:TAHOD-LITE NICOLE DE LA MATA | 2.45pm - 3.00pm Amphetamine-Type-Stimulant Use and HIV Infection: Findings from a Bio-Behavioral Survey of Men Who Have Sex with Men in Hanoi, Vietnam NGA VU | 2.40pm - 2.50pm HIV-funding Regimes: Let's Talk JOHN RULE 2.50pm - 3.00pm Defunding, refunding and maintaining peer-based services TBC | 2.30pm - 2.40pm HIV Treatment CHRISTINE SELVEY 2.40pm - 2.50pm Surveillance of behavioural risk MARTIN HOLT |
| | 3.00pm - 3.15pm HIV Gene Regulation by RNA Interference: Live Intracellular Tracking of RNA-Induced Transcriptional Silencing (RITS) Complex VERA KLEMM | 3.00pm - 3.15pm HIV Viral load suppression in adults and children receiving antiretroviral therapy - results for the IEDEA Collaboration AWACHANA JAMSAKUL | 3.00pm - 3.15pm Extending HIV Testing & Treatment to Young Key Populations: A Health-Systems Strengthening Approach in Indonesia ALISA PEDRANA | 3.00pm - 3.30pm Panel discussion | 2.50pm - 3.00pm PrEP update in NSW and the potential for reducing HIV transmission IRYNA ZABLOTSKA-MANOS |
| | 3.15pm - 3.30pm Monocyte can potentially reverse latency in pre-activation but not post-activation latently infected cells. SIMIN DOKHT REZAEI | 3.15pm - 3.30pm Fall in time from HIV diagnosis to Commencement of Antiretroviral Therapy 2011-2015 NICK MEDLAND | 3.15pm - 3.30pm Q&A | | 3.00pm - 3.30pm Panel discussion - Is the current HIV response enough to achieve a rapid decline in HIV transmissions? DARREN RUSSELL, MARK STOOVE, LEA NARISCO, NIC PARKHILL, JO HOLDEN, REBECCA GUY AND BILL WHITTAKER |
| 3.30pm - 4.00pm | AFTERNOON TEA Exhibition Hall | | | | |
| 4.00pm - 5.30pm | CONCURRENT 11: THEME A SYMPOSIUM ACH² SPONSORED SYMPOSIUM Room: Riverbank Room 8 Chairs: Anthony Cunningham and Gilda Tachedjian | CONCURRENT 12: THEME B PROFFERED PAPERS HIV COMORBIDITIES: ARE WE MEASURING AND RESPONDING APPROPRIATELY? Room: Riverbank Room 6 Chairs: Mark Bloch and David Nolan | CONCURRENT 13: THEME C PROFFERED PAPERS NEW APPROACHES TO HIV TESTING Room: Hall L Chairs: James Gray and Iryna Zablotska | CONCURRENT 14: SYMPOSIUM THEME C/D CROSS TRACK CHANGING CONCEPTS OF RISKS & IDENTITY ABOUT SERO-STATUS Room: Riverbank Room 7 Chairs: Bridget Haire and Martin Holt | |
| | | 4.00pm - 4.15pm Comparison of Different Tools Measuring Frailty in Australian Men Living With HIV JENNIFER HOY | 4.00pm - 4.15pm Delayed HIV testing among men who have sex with men in Australia has improved but remains an issue HUACHUN ZOU | 4.00pm - 4.15pm Socialising the biomedical turn SUSAN KIPPAX | |
| | | 4.00pm - 4.15pm Pre-clinical evaluation of a mucosal HIV vaccine strategy CHARANI RANASINGHE | | | |

CONFERENCE PROGRAM THURSDAY 17 NOVEMBER 2016

2016 AUSTRALASIAN HIV & AIDS CONFERENCE

THURSDAY, 17 NOVEMBER 2016

| | | | | |
|-----------------|--|---|---|---|
| 4.00pm - 5.30pm | 4.15pm - 4.30pm New Latency Reversing Agents specifically targeting HIV provirus positive cells JONATHAN JACOBSON | 4.15pm - 4.30pm Concomitant Medication Use in ART-Experienced Adults: Data from the PAART Study KRISTA SIEFRIED | 4.15pm - 4.30pm Time after time: Characteristics associated with high frequency testing at a peer-led HIV testing service in Australia KATHLEEN RYAN | 4.15pm - 4.30pm Biomedicine and serostatus borderlands among couples with mixed HIV status CHRISTY NEWMAN |
| | 4.30pm - 4.45pm Semen Demons: Immunosuppressive Factors Within Semen Modulate Anti-HIV-1 Cellular Immune Responses STEPHEN KENT / KEVIN SELVA | 4.30pm - 4.45pm Screening and Management Practices for Renal Disease in the HIV-Positive Patient Population of An Inner Metropolitan Sexual Health Service TAHIYA AMIN | 4.30pm - 4.45pm More than Just Friends? Exploring High Acceptability of Peer HIV Testing Among Men Who Have Sex with Men in Myanmar VANESSA VERONESE | 4.30pm - 4.45pm Shifts in thinking about HIV status and risk among men using PrEP DEAN MURPHY |
| | 4.45pm - 5.00pm Metabolic tests to predict HIV disease progression and immune functions in people living with HIV infection CLOVIS PALMER | 4.45pm - 5.00pm The Effect of Mental Health Referral on Symptoms of Depression among HIV Outpatients in Vietnam: A Three-Month Follow up Study THANH TRUC THAI | 4.45pm - 5.00pm HIV Self-Testing Doubles the Frequency of HIV Testing Among Higher-Risk Gay and Bisexual Men: A Randomised Controlled Trial (FORTH) MUHAMMAD JAMIL | 4.45pm - 5.00pm Informed sophistication: managing an HIV identity and risk in a bio-tech world BRENT ALLAN |
| | 5.00pm - 5.15pm CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles DI YU | 5.00pm - 5.15pm Associations between Periodontal Disease and Coronary Artery Disease in HIV-Positive Individuals VICTORIA BERQUIST | 5.00pm - 5.15pm The Use of HIV Self-Testing Kits to Test Partners Was Common Among Gay and Bisexual Men in an Australian Trial BENJAMIN BAVINTON | 5.00pm - 5.15pm Identity unhinged, can epidemiology keep pace? DENTON CALLANDER |
| | 5.15pm - 5.30pm New inhibitors to HIV KYLIE WAGSTAFF | 5.15pm - 5.30pm Substantial loss of bone mineral density in some patients receiving tenofovir-emtricitabine as HIV Pre-Exposure Prophylaxis ANDREW CARR | 5.15pm - 5.30pm Q&A | 5.15pm - 5.30pm Panel discussion |
| 5.30pm - 6.30pm | NETWORKING RECEPTION AND POSTER VIEWING Exhibition Hall | | | |

CONFERENCE PROGRAM **FRIDAY 18 NOVEMBER 2016**

2016 AUSTRALASIAN HIV & AIDS CONFERENCE

FRIDAY, 18 NOVEMBER 2016

| | | | | |
|-------------------|--|---|--|--|
| 6.30am | REGISTRATION OPENS | | | |
| | CASE PRESENTATION BREAKFAST <i>Room: Riverbank Rooms 7 & 8</i> <i>Chair: Martyn French</i> | | | |
| | 7.00am - 7.20am A Case of Chorea and Persistent Low Level Viraemia in a Human Immunodeficiency Virus (HIV)-Infected Patient GAWRI RAJAKARUNA | | | |
| 7.00am - 8.20am | 7.20am - 7.40am Case Report of a Treatment Naïve 4yo Boy with Positive HIV Serology and Undetectable Viral Load DANIEL YEOH | | | |
| | 7.40am - 8.00am Dual Pathologies: A Case of B Cell Lymphoma and Disseminated Tuberculosis in a Previously Well HIV Positive Individual ELOISE WILLIAMS | | | |
| | 8.00am - 8.20am Treponeme or Virus? Neurological Symptoms and Rash MICHAEL LOFTUS | | | |
| | PLENARY 3 <i>Room: Hall L</i> <i>Chairs: Stuart Turville and Susan Kippax</i> | | | |
| 8.30am - 10.00am | 8.30am - 9.00am Capturing the journey in 3D: Imaging HIV-cell interactions by 3D electron microscopy KEDAR NARAYAN, GROUP LEADER, CENTER FOR MOLECULAR MICROSCOPY (CMM), FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH, USA | | | |
| | 9.00am - 9.30am Towards elimination: parallels between hepatitis C and HIV models of care JOSEPH DOYLE, SPECIALIST IN INFECTIOUS DISEASES AND PUBLIC HEALTH MEDICINE, VIC, AUSTRALIA | | | |
| | 9.30am - 10.00am Stigma and discrimination in Timor Leste INES LOPES, EXECUTIVE DIRECTOR, ESTRELA +, TIMOR LESTE | | | |
| 10.00am - 10.30am | MORNING TEA EXHIBITION HALL | | | |
| | CONCURRENT 16: THEME A SYMPOSIUM BIOINFORMATICS - MAKING SENSE OF THE NUMBERS <i>Room: Riverbank Room 6</i> <i>Chairs: Chantelle Ahlenstiel and Steven Kent</i> | CONCURRENT 17: THEME B PROFFERED PAPERS ENGAGEMENT AND MAINTENANCE OF HIV CARE IN OUR REGION <i>Room: Riverbank Room 7</i> <i>Chair: Steve Wade</i> | CONCURRENT 18: THEME C PROFFERED PAPERS HIV PRE-EXPOSURE PROPHYLAXIS <i>Room: Hall L</i> <i>Chairs: Rebecca Guy and Darren Russell</i> | CONCURRENT 19: THEME D PROFFERED PAPERS SEXUAL AND REPRODUCTIVE HEALTH <i>Room: Riverbank Room 8</i> <i>Chairs: Jennifer Power</i> |
| 10.30am - 12.00pm | | | | |

CONFERENCE PROGRAM **FRIDAY 18 NOVEMBER 2016**

2016 AUSTRALASIAN HIV & AIDS CONFERENCE

FRIDAY, 18 NOVEMBER 2016

| | | | | |
|-------------------|---|--|---|---|
| 10.30am - 12.00pm | 10.30am - 11.00am The dynamics of the latent HIV reservoir JOHN MURRAY, PROFESSOR, UNSW, AUSTRALIA | 10.30am - 10.45am Knowledge of HIV status, enrollment in care and CD4 count among HIV-infected people who inject drugs in Vietnam DUONG CONG THANH | 10.30am - 10.45am Willingness to use HIV pre-exposure prophylaxis or have sex with someone using it: results of repeated national, online surveys MARTIN HOLT | 10.30am - 10.45am Low HIV Incidence amongst Pregnant and Postpartum Women Receiving a Lay Health Worker HIV Prevention Intervention in South Africa ASHRAF GRIMWOOD |
| | 10.45am - 11.00am Perceived Stigma is associated with non-adherence to Antiretroviral Treatment: A case study of a community-based SMS Reminders Campaign LIMIN MAO | 10.45am - 11.00am Acceptability of HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar BRIDGET DRAPER | 10.45am - 11.00am Expanded PrEP Implementation in Communities in NSW, Australia (EPIC-NSW): Evidence-Based Implementation Study IRYNA ZABLOTSKA-MANOS | 10.45am - 11.00am High HIV Positivity among Other Vulnerable Populations Reached Through Decentralized HIV Testing and Counselling in Myanmar SAI SAN MOON LU |
| | 11.00am - 11.30am Measuring HIV reactivation from latency MILES DAVENPORT, RESEARCHER, THE KIRBY INSTITUTE, UNSW, AUSTRALIA | 11.00am - 11.15am To Wait or not to wait? The effect of ARV resistance present at baseline on first line HIV treatments DORIS CHIBO | 11.00am - 11.15am Incidence and Associations with the Uptake of Methamphetamine Use among Gay and Bisexual Men MOHAMED HAMMOUD | 11.00am - 11.15am Tikobulabula': Conceptualization of Adolescent Sexual and Reproductive Well-Being in Fiji MICHELLE O'CONNOR |
| 11.30am - 12.00pm | 11.30am - 12.00pm Developing hand-it: The first HIV sequence-based diagnostic test for HIV-associated neurocognitive disorders KIERAN CASHIN, POSTDOCTORAL RESEARCH FELLOW, RMIT UNIVERSITY, VIC, AUSTRALIA | 11.15am - 11.30am Prevalence of integrase strand transfer inhibitor genotypic resistance following introduction of integrase inhibitors, 2012-2015 ANGIE PINTO | 11.15am - 11.30am Incidence and Associations with the Uptake of Methamphetamine Use among Gay and Bisexual Men MOHAMED HAMMOUD | 11.15am - 11.45am Title TBC UME WAINETTI |
| | | 11.30am - 12.00pm Poster Viewing Highlight Theme B | 11.30am - 11.45am What PrEP means for safe sex in Sydney: evolving norms BRIDGET HAIRE | 11.45am - 12.00pm Poster Viewing Highlight Theme D |
| | | 11.45am - 12.00pm Q&A | | |
| 12.00pm - 1.30pm | LUNCH Exhibition Hall | | | |
| 1.30pm - 3.00pm | CONCURRENT 20: THEME A PROFFERED PAPER HOST AND DRUG CONTROL OF HIV | CONCURRENT 21: THEME B SYMPOSIUM UPDATE ON HIV TREATMENT, PREP AND HEPATITIS: AUSTRALIAN GUIDELINES | CONCURRENT 22: THEME C PROFFERED PAPER HIV EPIDEMIOLOGY AND PREVENTION FOR GAY AND OTHER MEN WHO HAVE SEX WITH MEN | CONCURRENT 23: THEME D PROFFERED PAPER RETHINKING HIV STIGMA |
| | Room: Riverbank Room 6 Chairs: Charani Ranasinghe | Room: Hall L Chair: Julian Elliott | Room: Riverbank Room 7 Chairs: Wills Logue and Anthony Lyons | Room: Riverbank Room 8 Chairs: Enaam Oudih and Aaron Coale |

FRIDAY, 18 NOVEMBER 2016

| | | | | |
|-----------------|--|---|--|---|
| 1.30pm - 3.00pm | 1.30pm - 1.45pm Vaccination-Induced ICOS+ Circulating TFH Cells Exhibit Characteristics of Lymph Node TFH Cells But Are Dysfunctional and Th2-Skewed In HIV-1 Infection MARTYN FRENCH | 1.30pm - 1.45pm Switching antiretroviral therapy in virologically suppressed individuals JENNIFER HOY, PROFESSOR DIRECTOR, HIV MEDICINE, ALFRED HOSPITAL AND MONASH UNIVERSITY, VIC, AUSTRALIA | 1.30pm - 1.45pm Geographic Distribution of Gay and Bisexual Men on a Gay Dating Website GARRETT PRESTAGE | 1.30pm - 1.45pm Development of a National Monitoring System of Stigma among People Living With HIV in Australia CARLA TRELOAR |
| | 1.45pm - 2.00pm A novel mucosal HIV vaccination regimen involving live recombinant human rhinovirus and DNA vaccines to elicit protective HIV-specific immunity DANUSHKA WIJESUNDARA | 1.45pm - 2.00pm Monitoring and ensuring high quality and equity in HIV care VALERIE DELPECH, PUBLIC HEALTH CONSULTANT, PUBLIC HEALTH ENGLAND, UK | 1.45pm - 2.00pm Trends in the Incidence of HIV and Other Sexually Transmissible Infections among Male Sex Workers in Australia DENTON CALLANDER | 1.45pm - 2.00pm ART Use, Stigma and Disclosure: Changing Attitudes among PLHIV between 1997 and 2015 JENNIFER POWER |
| | 2.00pm - 2.15pm Activated Cytotoxic CD4 T Lymphocytes Containing Granzyme K during Primary Immune Responses to HIV-1, and to Vaccinia Inoculation JOHN ZAUNDERS | 2.00pm - 2.15pm PrEP and PEP guidelines update IRYNA ZABLOTSKA-MANOS, THE KIRBY INSTITUTE, UNSW, AUSTRALIA | 2.00pm - 2.15pm Changes in condom use with casual partners 2002-2014 in community-based surveys of HIV negative New Zealand gay and bisexual men PETER SAXTON | 2.00pm - 2.15pm Expert Views on the Needs of Heterosexually-Identified Men Who Have Sex with Men Regarding Sexual Health Promotion and Care CHRISTY NEWMAN |
| | 2.15pm - 2.30pm Under Restraints: Immunosuppressive Factors within Semen Repress Anti-HIV-1 Cellular Immune Responses KEVIN JOHN SELVA | 2.15pm - 2.30pm Hepatitis C guidelines update GAIL MATTHEWS, RESEARCHER, ST VINCENT'S HOSPITAL, NSW, AUSTRALIA | 2.15pm - 2.30pm Characteristics of Gay and Bisexual Men Who Use Little To No HIV Risk Reduction Strategies during Condomless Anal Intercourse JOHANN KOLSTEE | 2.15pm - 2.30pm Perceptions on HIV/Aids-Related Stigma and Discrimination in an Indonesian Prison: An Exploratory Study RITA KOMALASARI |
| | 2.30pm - 2.45pm A case study of HIV detection following post-exposure prophylaxis JULIAN LANGTON-LOCKTON | 2.30pm - 3.00pm Case study panel discussion | 2.30pm - 2.45pm Practising Biomedical Prevention Among Gay Men in Serodiscordant Relationships STEVEN PHILPOT | 2.30pm - 2.45pm Socio-Cultural Influences on the Perceptions of Nursing Students toward Caring for People Living with HIV/AIDS: Implications for Nursing Education DAVID PICKLES |
| | 2.45pm - 3.00pm Pharmacokinetic-Pharmacodynamic (PK-PD) Of Emtricitabine/Tenofovir Alafenamide (F/TAF) Demonstrated Wide Exposure Range Associated With Clinical Safety PAUL SLADE | | 2.45pm - 3.00pm G&A | 2.45pm - 3.00pm Online Preferences about Sex with HIV-Positive Partners GARRETT PRESTAGE |
| 3.00pm - 3.20pm | AFTERNOON TEA Foyer L | | | |

CONFERENCE PROGRAM **FRIDAY 18 NOVEMBER 2016**

2016 AUSTRALASIAN HIV & AIDS CONFERENCE

FRIDAY, 18 NOVEMBER 2016

| | |
|-----------------|---|
| 3.20pm - 4.15pm | PLENARY 4 <i>Room: Hall L</i> <i>Chairs: Bridget Haire</i> |
| | 3.20pm - 4.05pm HIV in 2020 - Imagining the Future: Panel Discussion JARED BAETEN, MATTHEW WAEIT, SUSAN KIPPAX, DARRYL O'DONNELL |
| | 4.05pm - 4.15pm Closing |
| 4.15pm | CONFERENCE CLOSE |

POSTER LISTING

2016 AUSTRALASIAN SEXUAL HEALTH CONFERENCE

| NO. | THEME | TITLE | FIRST NAME | LAST NAME |
|-----|---------------------------------------|---|-------------|-------------|
| 1 | Clinical Sexual Health & Epidemiology | Protective Antibody Responses to Vaccination for Hepatitis B in a Sydney Sexual Health/HIV Clinic. | Christopher | Sewell |
| 2 | Clinical Sexual Health & Epidemiology | Results of enhanced gonorrhoea surveillance in Western Sydney and Nepean Blue Mountains | Dillon | Adam |
| 3 | Clinical Sexual Health & Epidemiology | Contact Tracing for Gonorrhoea and Chlamydia by General Practitioners in Nepean Blue Mountains Local Health District. | Lisa | Allchin |
| 4 | Clinical Sexual Health & Epidemiology | A Retrospective Audit on the Diagnosis and Management of Genital Herpes at Clinic 275. | Megan | Ball |
| 5 | Clinical Sexual Health & Epidemiology | NPEP or PrEP | Charlotte | Bell |
| 6 | Clinical Sexual Health & Epidemiology | Impact on Microbiological Cure and Resistance of 1.5 G Extended Dose Azithromycin Versus 1g. | Catriona | Bradshaw |
| 7 | Clinical Sexual Health & Epidemiology | Donovanosis in Australia | Amy | Bright |
| 8 | Clinical Sexual Health & Epidemiology | Sex Work, HIV, and Sexually Transmissible Infections: A Study of Incidence among Women Attending Sexual Health Clinics | Denton | Callander |
| 9 | Clinical Sexual Health & Epidemiology | Delayed Diagnosis of Syphilis due to an Inappropriate Laboratory Test and Falsely Positive CMV IgM Result: A Case Study | Alana | Christensen |
| 10 | Clinical Sexual Health & Epidemiology | Post-Exposure Prophylaxis for HIV in a Primary Health Care Clinic for People who Inject Drugs | Karen | Chronister |
| 11 | Clinical Sexual Health & Epidemiology | 'I Don't Turn Every Consultation...Into A Sexual Health...Discussion' - General Practitioners' Perspectives on Promoting Sexual Health to Young Men | Archibald | Collyer |
| 12 | Clinical Sexual Health & Epidemiology | Significantly Improved Detection of Pharyngeal and Rectal Gonorrhoea by NAAT Compared to Culture in Men Who Have Sex with Men. | Vincent | Cornelisse |
| 13 | Clinical Sexual Health & Epidemiology | Increased Rates of Urethral Mycoplasma Genitalium in MSM at Western Sydney Sexual Health Centre. Implications for Future Screening. | Deborah | Couldwell |
| 14 | Clinical Sexual Health & Epidemiology | Correlates of Recent Testing Among Young Australians at Risk of Sexually Transmissible Infections | Caitlin | Douglass |
| 15 | Clinical Sexual Health & Epidemiology | Multiplexed Detection of STI Pathogens Using PlexZyme qPCR (PlexPCR): A Novel Real-Time Technology with a Superior Capacity for Multiplexing | Simon | Erskine |
| 16 | Clinical Sexual Health & Epidemiology | Sexual Health Clinic Follow Up of Emergency Department Results: It Works! | Rosalind | Foster |
| 17 | Clinical Sexual Health & Epidemiology | Sexual health risks and help-seeking behaviours of south Asian men who have sex with men (SAMSM) living in Australia | Ahm | Haque |

| NO. | THEME | TITLE | FIRST NAME | LAST NAME |
|-----|---------------------------------------|---|------------|------------------|
| 18 | Clinical Sexual Health & Epidemiology | Increasing STI and BBV Testing in Aboriginal Community Controlled Health Services – A Whole of Service Approach | Kaylie | Harrison |
| 19 | Clinical Sexual Health & Epidemiology | Urine Collected with a FLOQSwab™ Provides a Robust Sample for Testing for C. Trachomatis with the Roche Cobas® Ct/Ng Test | David | Hawkes |
| 20 | Clinical Sexual Health & Epidemiology | Anal HPV and Associated Cytological Changes in Renal Transplant Recipients | Richard | Hillman |
| 21 | Clinical Sexual Health & Epidemiology | Nine Years On: Increasing Access for MSM to Sexual Health Clinics in an Outer Metropolitan Area – A Clinical Perspective. | Naomi | Hoffman |
| 22 | Clinical Sexual Health & Epidemiology | Are Australian Approaches for Partner Notification Feasible for the Chilean Context? | Nicole | Iturrieta-Guaita |
| 23 | Clinical Sexual Health & Epidemiology | Seasonal Variation in Gonorrhoea among Men Who Have Sex with Men | Bin | Li |
| 24 | Clinical Sexual Health & Epidemiology | Human Papillomavirus (HPV) Prevalence, Awareness and Vaccine Acceptability in High Risk Men Who Have Sex with Men in New Zealand | Adrian | Ludlam |
| 25 | Clinical Sexual Health & Epidemiology | Surveillance of Sexually Transmitted Infections (STI) in Sri Lanka: Experiences from a Resource Constrained Setting | Ariyaratne | Manthunge |
| 26 | Clinical Sexual Health & Epidemiology | Slip and Slide: Findings from the Sexual Activity after Breast Cancer (SAB) Study | Jennifer | Marino |
| 27 | Clinical Sexual Health & Epidemiology | Barriers to Chlamydia Screening of Young People and Possible Solutions as Reported by General Practitioners in Victoria and NSW | Clarissa | Moreira |
| 28 | Clinical Sexual Health & Epidemiology | Partner Notification Outcomes for Men Who Have Sex with Men Diagnosed with Syphilis Referred to Partner Notification Officers, Melbourne, Australia | Jason | Ong |
| 29 | Clinical Sexual Health & Epidemiology | Clinical Characteristics of Herpes Simplex Virus Urethritis Compared with Chlamydial Urethritis among Men | Jason | Ong |
| 30 | Clinical Sexual Health & Epidemiology | Treatment Outcomes for Rectal Lymphogranuloma Venereum in Men Who Have Sex with Men: A Review of Clinical Cases | Jason | Ong |
| 31 | Clinical Sexual Health & Epidemiology | Chem-Sex is More Frequently Associated with Accessing Post Exposure Prophylaxis in Men Who Have Sex with Men | Daniel | Richardson |
| 32 | Clinical Sexual Health & Epidemiology | Grindr Use by Men Who Have Sex with Men (MSM) is Associated with High Rates of Bacterial Sexually Transmitted Infections | Daniel | Richardson |
| 33 | Clinical Sexual Health & Epidemiology | Sexual Practices and Oral HPV Status of Patients Attending General Dental Surgery | Beata | Rumianek |
| 34 | Clinical Sexual Health & Epidemiology | Rural Outreach for Sexual Health & Blood Borne Virus Testing | Anni | Slater |
| 35 | Clinical Sexual Health & Epidemiology | Measuring Female Genital Self-Image in an Australian Population, Is there an Effective Tool? | Meredith | Temple-Smith |
| 36 | Clinical Sexual Health & Epidemiology | Concordance of Syphilis Infection Between Same Sex Male Partners Attending a Sexual Health Clinic in Melbourne, Australia: A Cross-Sectional Study. | Janet | Towns |
| 37 | Clinical Sexual Health & Epidemiology | Increasing Macrolide Treatment Failure in Women with Mycoplasma Genitalium in a Public Hospital | Saima | Wani |

| NO. | THEME | TITLE | FIRST NAME | LAST NAME |
|-----|---------------------------------------|--|------------|------------|
| 38 | Clinical Sexual Health & Epidemiology | The Emergence of Azithromycin Resistant Gonorrhoea in South Australia | Alison | Ward |
| 39 | Clinical Sexual Health & Epidemiology | Would it be Acceptable to Withhold Epidemiological Treatment in Asymptomatic Gay Men who present as a Contact of Gonorrhoea? | Simon | Wright |
| 40 | Clinical Sexual Health & Epidemiology | Prevalence and Risk Factors of Human Papillomavirus among MSM in Taiwan: Results from a Community Sample | Huachun | Zou |
| 41 | Education & Health Promotion | Let's Talk: Exploring Sexuality Education in Australian Schools to Meet the Needs of Young Women | Sienna | Aguilar |
| 42 | Education & Health Promotion | Improving Sexual Health Knowledge in Rural and Remote South Australian Aboriginal Communities | Susan | Arwen |
| 43 | Education & Health Promotion | Inequity in Access to Pregnancy Related Services and Contraception for International Students | Georgia | Babatsikos |
| 44 | Education & Health Promotion | Taboo or Not Taboo? Sexual Health Education through Community Engagement with Young People in Aboriginal Community Controlled Health Services | Sarah | Betts |
| 45 | Education & Health Promotion | Making Patient Delivered Partner Therapy for Chlamydia Feasible; Implementation and Early Findings from the ADOPT Study. | Chris | Bourne |
| 46 | Education & Health Promotion | Integrating Sexual Health into Youth Early Intervention Mental Health Services | Marnie | Britton |
| 47 | Education & Health Promotion | Is Headspace the Best Place to Conduct Sexual Health Screening? | Anisa | Cheshire |
| 48 | Education & Health Promotion | Primary Health Care Nurses Undertaking Clinical Placements at Publicly Funded Sexual Health Services; Can It Be Done? Is It Worthwhile? | Phoebe | Chomley |
| 49 | Education & Health Promotion | A Regional Advocacy Agenda on Trans* Health and Sexual Health among Transgender People in the ISEAN Region | Raine | Cortes |
| 50 | Education & Health Promotion | Predicting Macrolide Resistance: Correlation of Clinical Outcome and Laboratory Results Using Plexpctm M. Genitalium Resistanceplustm Assay (Speedx) | Deborah | Couldwell |
| 51 | Education & Health Promotion | 'Talking Out Loud': WA Medical Students' Views of Sexual Health Teaching | Alison | Creagh |
| 52 | Education & Health Promotion | Are University Sexual Health Promotions Serving Those Who Need Them Most? A Cross-Sectional Study | Matthew | Dunn |
| 53 | Education & Health Promotion | A Multi-Disciplinary Collaboration to Improve Recognition of PID | Natalie | Edmiston |
| 54 | Education & Health Promotion | Doin 'It' Right! An Adaptable Culturally Appropriate Resource for Working with Aboriginal Young People around Sexual and Reproductive Health. | Kaylie | Harrison |
| 55 | Education & Health Promotion | Initiatives to Improve Sex Worker Access to STI Screening in Sydney Local Health District. | Barbara | Hatten |
| 56 | Education & Health Promotion | A Qualitative Meta-Synthesis of Young Peoples' Experiences of Sending and Receiving Sexual Messages and Images via Hand Held Devices ('Sexing') | Mark | Hayter |
| 57 | Education & Health Promotion | Take Blaktion: Using Comedy to Engage Aboriginal Young People around Sexual Health | Gemma | Hearnshaw |

| NO. | THEME | TITLE | FIRST NAME | LAST NAME |
|-----|------------------------------|--|------------|-----------------|
| 58 | Education & Health Promotion | Intersectoral Perceptions of Young People's Sexual Health | Alana | Hulme Chambers |
| 59 | Education & Health Promotion | 'Your Fertility' - Evaluation of a Health Promotion Program to Improve Awareness of Factors That Affect Fertility | Louise | Johnson |
| 60 | Education & Health Promotion | Evaluation of 2014 STI/HIV Testing Guidelines for Asymptomatic Men who have Sex with Men among General Practitioners in Sydney | Shih-Chi | Kao |
| 61 | Education & Health Promotion | Implementing Sexual Health Messages to Vulnerable Young People in Western Sydney for Youth Week 2016 | Jade | Lane |
| 62 | Education & Health Promotion | General Practitioner's and Access to Sexual Health Clinics and Online Resources: A Nepean and Blue Mountains Perspective | Julian | Langton-Lockton |
| 63 | Education & Health Promotion | Community Pharmacist Perceptions and Attitudes toward Dispensing Hepatitis B and C Medicines | Esther | Lau |
| 64 | Education & Health Promotion | A Systematic Review of Reviews on Interventions to Improve the Sexual and Reproductive Health of Young People | Megan | Lim |
| 65 | Education & Health Promotion | 'It's Our Choice' - A Health Promotion Initiative to Assist Women Experiencing Homelessness in Overcoming Barriers to Cervical Cancer Screening | Renee | Lovell |
| 66 | Education & Health Promotion | Smoking Reduction and Cessation Support Project for Sex Workers Attending Sydney Sexual Health Centre (SSHC) | Lynne | McCormack |
| 67 | Education & Health Promotion | Culturally and Linguistically Diverse Background (CALD) Industry Sex Workers in South West Sydney Local Health District (SWSLHD): A Health Promotion Perspective | Lidya | McGowan |
| 68 | Education & Health Promotion | TALAR For SRE: An Innovative Tool for Providing Sexuality Education to People with Disabilities | Sandra | Norman |
| 69 | Education & Health Promotion | A Major Role for the STIGMA Action Group in Inner Sydney: Increase Access, Skills and Knowledge of General Practitioners | Hanna | Pak |
| 70 | Education & Health Promotion | Sexual Health Education Made Easy in SA Primary Schools | Brydie | Pedler |
| 71 | Education & Health Promotion | SMS4Health: Reaching Young People with Health Promotion Messages to Improve Adolescent Sexual and Reproductive Health and Reduce Smoking in Indonesia. | Alisa | Pedrana |
| 72 | Education & Health Promotion | SMS4Health: Understanding How to Reach Young People with Health Promotion Messages in Indonesia. | Alisa | Pedrana |
| 73 | Education & Health Promotion | Essentially Sexual - Doing It in Large Groups in the Name of Education | Michael | Rodriguez |
| 74 | Education & Health Promotion | Baby Think it Over | Christina | Self |
| 75 | Education & Health Promotion | Life Happens-Translating the Results of Sexual Health Research Into a Resource for Young People | Kate | Senior |
| 76 | Education & Health Promotion | Sexuality-Related Attitudes Significantly Modulate Demographic Variation in Sexual Health Literacy in Tasmanian University Students | Steve | Simpson, Jr. |
| 77 | Education & Health Promotion | HIV101: An Organisational Development Approach | Holley | Skene |

| NO. | THEME | TITLE | FIRST NAME | LAST NAME |
|-----|------------------------------|--|------------|----------------|
| 78 | Education & Health Promotion | Voices of Sexuality Education: Giving Voice to Opinions of a Diverse Range of Young People, Families and Communities. | Kylie | Stephens |
| 79 | Education & Health Promotion | "So, What Should I Do?" Talking Sexual Health To International Students | Budi | Sudarto |
| 80 | Education & Health Promotion | Private Sex Workers in Sydney - A Cross-Sectional Study of Advertised Sexual Services using a Web Based Search. | Caroline | Thng |
| 81 | Education & Health Promotion | Engagement of Private Sex Workers with Sexual Health Services - An Online Survey | Caroline | Thng |
| 82 | Education & Health Promotion | Development and implementation of Point-of-Care HIV testing in high risk populations in Tasmania | El | Thompson |
| 83 | Education & Health Promotion | Improving STI/BBV Testing and Management in Aboriginal Community Controlled Health Services: A Systematic Review of What Works, What Doesn't. | Monika | Wadolowski |
| 84 | Education & Health Promotion | Profile and Frequency of Meeting Sexual Partners Online in Australia | Lucy | Watchirs Smith |
| 85 | Education & Health Promotion | The Perspectives of Primary Healthcare Workers on Sexual Assault and Sexually Transmitted Infections (STIs) in North Sulawesi, Indonesia | Olivia | Waworuntu |
| 86 | Psycho-Social | Assessing Evidence-Based Practice in Australian Abortion Service. | Tamara | Baillie |
| 87 | Psycho-Social | The Ten Year Evolution of Transgender Health Care in a Far North Queensland Sexual Health Service | Susan | Davies |
| 88 | Psycho-Social | Born This Way: The Psychosocial Implications of Surgical Intervention during Infancy on Individuals with Intersex Variations. | Mandy | Henning-ham |
| 89 | Psycho-Social | Assessing for Psychopathology in Sexual Health Populations | David | Tuck |
| 90 | Reproductive Health | The Initiative for Multipurpose Prevention Technologies (IMPT): Building the Movement | Deborah | Bateson |
| 91 | Reproductive Health | Pregnancy Recurrence and Complications after Terminations: An Audit of Abortions in South Australia. | William | Breidahl |
| 92 | Reproductive Health | Emergency Contraception Update | Helen | Calabretto |
| 93 | Reproductive Health | Unmet Need for Contraception in Bangladesh: A Secondary Data Analysis of the 2014 Bangladesh Demographic Health Survey | Mahruba | Khanam |
| 94 | Reproductive Health | Overcoming Barriers to Uptake of Long Acting Reversible Contraception among Women: A Qualitative Study among Clients of Hairdressers in Zimbabwe | Memory | Makamba |
| 95 | Sexuality | Disability, Sexuality and Quality of Life: The Missing Discourse | Laura | Grozdanovski |

POSTER LISTING

2016 AUSTRALASIAN HIV & AIDS CONFERENCE

| NO. | THEME | TITLE | FIRST NAME | LAST NAME |
|-----|---------|--|------------|-------------|
| 1 | Theme A | The New and Improved Alere HIV Combo, How Does it Compare to its Predecessor? | Ashleigh | Cameron |
| 2 | Theme A | Drug Resistance among Women Attending Antenatal Clinics in Ghana | Philip | Enyan |
| 3 | Theme B | Longer Term Safety of Tenofovir Alafenamide in Renal impairment | Mark | Bloch |
| 4 | Theme B | Renal Safety of Tenofovir Alafenamide in Patients at High Risk of Kidney Disease | Robert | Finlayson |
| 5 | Theme B | STRIIVING: Switching to Abacavir/Dolutegravir/Lamivudine Fixed Dose Combination from a PI, NNRTI or INI-Based Regimen Maintains HIV Suppression at Week 48 | Michael | Aboud |
| 6 | Theme B | Superior Efficacy of Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination vs Ritonavir-Boosted Atazanavir plus Tenofovir/Emtricitabine in Treatment-Naïve Women with HIV-1 Infection (ARIA Study) | Michael | Aboud |
| 7 | Theme B | Dolutegravir Based Regimens (Dbrs) Viral Load Decay at Week 4 Could Predict Sustained Viral Suppression at Week 96 | Pedro | Eitz Ferrer |
| 8 | Theme B | Safety and Efficacy of Dolutegravir by Age, Race and Gender: Subgroup Analysis of 96wk Results from Treatment-Naïve Phase III Trials | Mark | Bloch |
| 9 | Theme B | Rate and predictors of Integrase Inhibitor-uptake at Melbourne Sexual Health Centre | Kate | Mackie |
| 10 | Theme B | A Retrospective Clinical Audit of General Practices in Australia to Determine the Motivation for Switch to DTG/ABC/3TC and Clinical Outcomes. | Pedro | Eitz Ferrer |
| 11 | Theme B | Experiences and Expectations of Participants Completing HIV Cure Focused Clinical Trials | James | McMahon |
| 12 | Theme B | Who Attends Community-Based HIV Testing Services? Results from the Gay Community Periodic Surveys | Evelyn | Lee |
| 13 | Theme B | Quality aspects of HIV Point-of-Care Testing in remote community-based settings in New South Wales | Claudette | Satchell |
| 14 | Theme B | Audit of Methods to Maximise Appointment Attendance across Different Models of HIV Care | James | McMahon |
| 15 | Theme B | Barriers to HIV Medication Adherence: For People with Mental Health Diagnosis and/or Problematic Use of Alcohol or Drugs. | Danny | Barnes |
| 16 | Theme B | Pharmacist perceptions and attitudes toward dispensing HIV medicines in the community | Lisa | Nissen |
| 17 | Theme B | Assessment of the Incidence and Time to Treatment of STIs in a HIV-Positive MSM Cohort from a Tertiary HIV Service. | Thornton | Macauley |

| NO. | THEME | TITLE | FIRST NAME | LAST NAME |
|-----|---------|---|------------|-------------|
| 18 | Theme B | Characteristics of HIV Patients at Albion Centre Without a Regular GP | Mithilesh | Dronavalli |
| 19 | Theme B | Cardiovascular Risk Outweighs Fracture Risk Though Both Are Correlated in a Heterogenous Australian HIV Cohort | Su Mei | Goh |
| 20 | Theme B | Addressing Smoking in Routine Health Care of People Living With HIV: The Practices and Attitudes of Australian Health Care Providers | Stephanie | Bell |
| 21 | Theme B | Uptake of Pneumococcal Vaccination in New HIV Positive Clients Attending Sydney Sexual Health Centre Over a Four Year Period | Cherie | Desreux |
| 22 | Theme B | Delivering the Resources to Support Effective HIV Care in NSW | Sharon | Robinson |
| 23 | Theme B | A Mobile Technology Enhanced Electronic Medical Record/Clinical Decision Support System for Perinatal HIV Management: A Case Study from Kenya | Neel | Arant Bandy |
| 24 | Theme B | Advocacy and Collaboration: First HIV Pregnancy for a Regional Service | Catherine | Orr |
| 25 | Theme B | Early Height and Weight Changes in Asian Children Using Cotrimoxazole Prophylaxis with Antiretroviral Therapy | David | Boettiger |
| 26 | Theme B | Treatment Efficacy of Doxycycline for Rectal Lymphogranuloma Venereum in Men Who Have Sex with Men: A Systematic Review and Meta-Analysis | Jason | Ong |
| 27 | Theme B | Eliminating hepatitis C transmission among people with HIV co-infection by enhancing care and treatment: the co-EC Study cohort characteristics | Joseph | Doyle |
| 28 | Theme B | High Efficacy of Elbasvir/Grazoprevir (EBR/GZR) in HCV Genotype 1, 4, and 6-Infected Patients With HIV Coinfection | Mark | Bloch |
| 29 | Theme B | Sofosbuvir/Velpatasvir Single-Tablet Regimen for 12 Weeks in Patients Co-Infected With Hcv and Hiv-1: The Phase 3 Astral-5 Study | Gail | Matthews |
| 30 | Theme B | Double Trouble: Treating HIV-HCV Coinfection in General Practice | David | Baker |
| 31 | Theme B | A Holiday to Remember: Tenofovir-Induced Osteomalacia | Brittany | Knezevic |
| 32 | Theme B | Tuberculous Meningoencephalitis and Cerebral Toxoplasmosis in HIV patient with Stevens Johnson syndrome: a case report | Siti | Nurlaela |
| 33 | Theme B | Case study: Cutaneous vasculitis in setting of starting dolutegravir | Vincent | Cornelisse |
| 34 | Theme B | Screening and Management of Cardiovascular Disease Risk Factors in HIV-Positive Patients | Tahiya | Amin |
| 35 | Theme B | A Snapshot of Neuropsychological Health in a "50-Something Aged" Cohort of People Living with Chronic HIV Infection | Susan | Herrmann |
| 36 | Theme B | Comparison between Metropolitan and Regional HIV Medical and Nursing Care based on European AIDS Clinical Society Guidelines (2015) | Louise | Holland |

| NO. | THEME | TITLE | FIRST NAME | LAST NAME |
|-----|---------|---|------------|-------------|
| 37 | Theme B | Maintaining Engagement in Care and HIV Suppression in Patients with Mental Health and Substance Abuse Co-Morbidities: Outcomes of an Audit | John | McAllister |
| 38 | Theme B | The Evolution of a Rural HIV Service for Refugee Women | Catherine | Orr |
| 39 | Theme B | Development of CALD Focused HIV Peer Support Model | Namam | Salih |
| 40 | Theme B | Missed and Late diagnosis of HIV- Back to the Future | Olivia | Smibert |
| 41 | Theme C | Methods to prevent HIV transmission used by homosexual male serodiscordant couples in three countries | Benjamin | Bavinton |
| 42 | Theme C | Title: Surveying tenofovir resistance in the Western Australia HIV cohort. | Alison | Castley |
| 43 | Theme C | HIV Pre-Exposure Prophylaxis (PrEP): Lessons from Implementation in an Australian General Practice. | Vincent | Cornelisse |
| 44 | Theme C | The Meaning of "Regular Partner" Amongst Men Who Have Sex with Men in Australia; A Cross-Sectional Analysis. | Vincent | Cornelisse |
| 45 | Theme C | ISEAN-Hivos Philippines: Strengthening Capacities of Community-Based Organizations (CBO) through Organizational Development (OD) for Sustainability of Community-led HIV and Rights-based Interventions | Raine | Cortes |
| 46 | Theme C | Chasing The Possible: Are We There Yet? Innovations in Testing to End the HIV Epidemic in NSW, Australia | Timothy | Duck |
| 47 | Theme C | Associations with PrEP Uptake among Gay and Bisexual Men | Mohamed | Hammoud |
| 48 | Theme C | Party Drug Use and Sexual Risk Behaviours among Gay and Bisexual Men | Mohamed | Hammoud |
| 49 | Theme C | The lived experience of sexual life with HIV: Sexual adjustment, functioning and new factors in sex lives due to PrEP | Ben | Huntingdon |
| 50 | Theme C | Trends and Predictors of Recent HIV Testing Over 22 Years among a Clinic Sample of MSM in South Australia | Mikko | Li |
| 51 | Theme C | Dolutegravir with Tenofovir Disoproxil Fumarate - Emtricitabine as HIV Post-Exposure Prophylaxis in Gay and Bisexual Men | John | McAllister |
| 52 | Theme C | HIV "Not Further Specified": The Limitations in Classifying and Reporting Heterosexual Exposure to HIV | Clarissa | Moreira |
| 53 | Theme C | Diagnosis of latent and active tuberculosis in HIV-infected patients in a large, tertiary centre cohort in Melbourne, Australia | Ramona | Muttucumaru |
| 54 | Theme C | Evaluation of the Impact of Grindr Advertisements on Website Traffic and HIV Testing at a Regional Sexual Health Clinic | Michael | O'Reilly |
| 55 | Theme C | Negotiating HIV in the Sexual and Everyday Lives of Gay Men in Serodiscordant Relationships | Steven | Philpot |
| 56 | Theme C | Bringing Our People with Us - Gay Community Forums | Gavin | Prendergast |

| NO. | THEME | TITLE | FIRST NAME | LAST NAME |
|-----|---------|--|------------|-----------|
| 57 | Theme C | Use of Erectile Dysfunction Medications and Risk Behaviour among Gay and Bisexual Men | Garrett | Prestage |
| 58 | Theme C | HIV and Aging: Demographic Changes in the Asia-Pacific Region | Rainer | Puhr |
| 59 | Theme C | Latecomers – A Regional Pilot Study Of Delayed HIV Presentation | Richard | Riley |
| 60 | Theme C | Pop-up HIV testing at community events: a successful and acceptable addition to the PRONTO! testing model | Kathleen | Ryan |
| 61 | Theme C | How did you hear about us? Characterising men by the method they found out about a new HIV testing service | Kathleen | Ryan |
| 62 | Theme C | Trends in HIV diagnoses in New Zealand 1985-2014: Three decades of national monitoring | Peter | Saxton |
| 63 | Theme C | Changes in condom use with casual partners 2002-2014 in community-based surveys of HIV positive New Zealand gay and bisexual men | Peter | Saxton |
| 64 | Theme C | The Relationship between Quality of Life, Psychological Distress and Coping Strategies of Persons Living With HIV/AIDS in Cairo, Egypt | Salem | Shalaweh |
| 65 | Theme C | Delivering the Resources to Support Effective HIV Care in NSW | Barbara | Telfer |
| 66 | Theme C | Amphetamine-type stimulant (ATS) use among people who inject drugs (PWID) in Vietnam - 8 provinces, 2013 | Duong Cong | Thanh |
| 67 | Theme C | Seek, Test, Re-Test: Characteristics of High Frequency HIV Testers among Service-Engaged Men Who Have Sex with Men in Myanmar | Vanessa | Veronese |
| 68 | Theme C | The Relationship between Methamphetamine, Condomless Anal Intercourse and Sexual Sensation Seeking Among Men Who Have Sex with Men in Vietnam | Nga | Vu |
| 69 | Theme C | I'm Ending HIV – Authentic Storytelling to Influence Testing Behaviours and Knowledge of Prep | Mike | Wacher |
| 70 | Theme C | Reasons for testing among NSW residents newly diagnosed with HIV 2011-2015 | Meredith | Wickens |
| 71 | Theme C | Post-Exposure Prophylaxis for HIV - What Else to Consider? | Elisabeth | Wilkinson |
| 72 | Theme C | Repeat HIV testing and early HIV diagnosis among clients attending voluntary counselling and testing (VCT) clinics in Wuxi, China | Huachun | Zou |
| 73 | Theme D | Barriers to Accessing HIV-Related Support Services among (Primarily) Heterosexual HIV Service Users: Results from the Pozhet Periodic Survey 2016. | Danny | Barnes |
| 74 | Theme D | Examining the Benefits to Women Living with HIV of a Community Organisation-Led Research Project | Alison | Boughey |
| 75 | Theme D | Standards for Psychosocial Support for Adults Living with HIV | Megan | Campbell |
| 76 | Theme D | A New Frontier: PASH.Tm in the HIV Health Promotion Space | Ted | Cook |
| 77 | Theme D | Alcohol and Other Drug (AOD) / HIV Integrated Care Project | Dee | Holland |

| NO. | THEME | TITLE | FIRST NAME | LAST NAME |
|-----|---------|--|------------|-------------|
| 78 | Theme D | Parenting Desires, Expectations and Sperm Donation among HIV Positive Gay Men | Jen | Johnson |
| 79 | Theme D | Eat Well, Live Well With HIV – Addressing Food Insecurity for Clients with HIV | Richard | Kennedy |
| 80 | Theme D | Sew Tanzania: Showcasing the Resilience of HIV+ Women in Tanzania | Nicki | Lees |
| 81 | Theme D | Non- Government Organisations Response to HIV in Smaller Jurisdictions: The Benefits of Cross Border Collaborations, to Improve HIV Services for Gay Men, MSM, and People Living with HIV in South Australia | Wills | Logue |
| 82 | Theme D | Collective Resilience as a Protective Factor for the Mental Health of Gay Men Living With HIV | Anthony | Lyons |
| 83 | Theme D | Consumer Involvement in the Design, Delivery and Efficacy of a HIV Clinical Service | David | Murray |
| 84 | Theme D | Wisdom of the Crowds: Key Informant Interviews Evaluating a Crowdsourced Logo Contest for an International HIV Conference | Jason | Ong |
| 85 | Theme D | The Importance of Enabling Environment: The Impact of Crackdowns on HIV Prevention and Treatment among PWID In Myanmar | Sai | San Moon Lu |

CPD accreditation application in progress



VIROLOGY COURT

During Australasian Sexual Health Conference 2016 (ASHM)*

YOUR JURY SUMMONS TO APPEAR†

DATE: 17 NOVEMBER 2016

TIME: 6:30 – 8:00PM

COURTHOUSE: THE BALLROOM, INTERCONTINENTAL HOTEL, ADELAIDE

Your participation as a juror is requested at the Virology Court. Join your fellow jurors to hear the scientific cases for F/TAF and ABC/3TC backbones. Hear the latest data, compare and contrast the results and render your verdict.

Substantial food and beverages will be served from 6:30 - 7:00pm.

REGISTER NOW AT:

www.eventful.com.au/virologycourt

Enquiries | Gilead Secretariat T | +61 2 9698 8055 E | gileadsvp@eventful.com.au

* Virology Court is not part of the official ASHM program

† Space is extremely limited and available on a first-come, first-served basis



**HONOURABLE JUDGE
DAVID COOPER**
SCIENTIA PROFESSOR

The Kirby Institute
University of New South
Wales, Australia



**COUNSELLOR FOR F/TAF
MARK BOYD**
PROFESSOR OF MEDICINE

University of Adelaide
Australia



**COUNSELLOR FOR ABC/3TC
DICK QUAN**
DIRECTOR

Holdsworth House
Sydney, Australia

Gilead is committed to protecting the privacy of your personal information and complies with the Australian Privacy Act 1988 (Cth) to ensure that your personal information is protected. Gilead handles all of your personal information in accordance with Gilead's Privacy Policy and Personal Information Collection Statement which have been provided to you and/or can be accessed at <http://www.gilead.com/about/worldwide-operations/australia>. From time to time, Gilead may also provide you with marketing material about Gilead's products and services including by email, SMS and telephone call and you consent to Gilead using your personal information for this purpose. If you do not want to receive information about Gilead products or services, you can withdraw your consent at any time by contacting the Privacy Officer at Gilead's address below or by unsubscribing using an unsubscribe facility in an email or SMS. If you have any queries about how Gilead handles your personal information or would like to access or correct your personal information, please write to: Privacy Officer, Gilead Sciences Pty Ltd, Level 6, 417 St Kilda Road, Melbourne, 3004. Gilead Sciences Pty Ltd, Australia & New Zealand, Level 6, 417 St Kilda Road, MELBOURNE 3004. Date of Preparation: July 2016. Etal6456.



NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

— AUSTRALASIAN —

20 HIV & 17 AIDS

— CONFERENCE —

8-10 NOVEMBER 2017 • CANBERRA

www.hivaidconference.com.au

SAVE THE DATE

— AUSTRALASIAN —

20 SEXUAL 17 HEALTH

— CONFERENCE —

8-10 NOVEMBER 2017 • CANBERRA

www.shconference.com.au

